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CD137 is a member of the tumour necrosis factor receptor (TNFR) 
superfamily that is expressed on a variety of immune cells. Its activation 
provides co-stimulatory signals to T cells and preferentially induces 
proliferation and activation of CD8 T cells. Similar to CD137, its ligand 
(CD137L), is also a membrane bound protein. Interaction between CD137 and 
CD137L not only induces signalling into the receptor bearing cell, it also 
initiates signalling into the ligand bearing cell. Hence, CD137 and its ligand 
participate in bidirectional signalling and stimulation of CD137L which 
results in signalling into ligand bearing cells has been termed as CD137 
reverse signalling.  
In human monocytes, CD137L signalling delivers a potent activating signal. 
However, characterization of monocyte activation by CD137L has been 
restricted to the production of pro-inflammatory cytokines, adherence and 
morphological changes. This study shows that treatment of monocytes with 
recombinant CD137 protein, which stimulates CD137L on monocytes, also 
induces their differentiation to dendritic cells (DCs). This is evidenced by the 
increased endocytic capacity, up-regulation of co-stimulatory molecules and 
the ability to induce proliferation of naïve T cells. CD137 not only induces 
monocyte to DC differentiation but also promotes DC maturation. These DCs 
in turn inhibit development of regulatory T cells but induce T cell expression 
of perforin, IFN-, IL-13 and IL-17 and T cells with a high killing activity. 
Hence, recombinant CD137 protein as a sole factor can induce differentiation 
of monocytes to mature, inflammatory DCs that have a potent T cell 
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stimulatory capacity. As such, CD137 show potential in generating DCs that 
can be used in human immunotherapy.  
In contrast to these T cell stimulatory activities, CD137L stimulated 
monocytes also induce T cell apoptosis. CD137 mediated, monocyte 
dependent T cell apoptosis requires direct cell to cell contact and occurs 
independently of the extrinsic pathway of apoptosis. Instead, ROS are 
implicated in mediating T cell apoptosis. Hence, this study shows two 
contrasting activities of CD137L stimulated monocytes that are temporally 
separated; early induction of T cell apoptosis that is followed by its T cell 
stimulatory function.  
The pattern of CD137 induced, monocyte dependent T cell apoptosis show 
close similarities to infection induced T cell attrition which occurs during a 
number of viral infections. This early T cell apoptosis is suggested to be 
beneficial to the subsequent development of pathogen specific immune 
responses by (1) creating space in the lymphoid organ for expansion of 
antigen specific T cells and (2) depleting low affinity cross reactive T cells 
that can impede the development of proper immune responses. Hence, the two 
phases of CD137L mediated monocyte activation seem to be geared towards 
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This thesis focuses on the activities of CD137 ligand (CD137L) activation on 
monocytes, a subtype of myeloid cells. Hence, this introduction gives an 
overview of the protein of interest, CD137, and its interaction with its ligand. 
The concept of reverse signalling will be addressed and current literature on 
the effects of CD137 reverse signalling is highlighted. Further, a review on 
the current knowledge of monocytes, their differentiation, function and 
interactions with T cells is discussed. Lastly, the research objectives of the 
thesis are presented that will be further elaborated in the results and discussion 
section.  
 
1.1 The CD137 biology      
1.1.1 The CD137 protein 
CD137 was originally termed 4-1BB and induced by lymphocyte activation 
(ILA) in mice and humans, respectively. It is a member of the tumour necrosis 
factor receptor family, specifically, superfamily 9 (TNFRSF9). This protein 
was first identified in activated murine T lymphocytes. In mice, CD137 is a 
13kb gene on chromosome 4 (Kwon and Weissman, 1989). The full length 
cDNA of the human homologue was finally characterized in 1993 (Schwarz et 
al, 1993). It is a type I transmembrane protein and the gene is located on 
chromosome 1p36 with other members of the TNFR family (Schwarz et al, 
1997). 
The nucleotide sequence of CD137 is made up of eight exons and seven 




amino acid (aa) protein. The first 23 aa are characteristic of a signal peptide 
which is followed by a cysteine rich extracellular domain, constructed from 
six exons, a hydrophobic transmembrane domain and a cytoplasmic tail 
(Vinay and Kwon, 2006). These features indicate that CD137 is a cell surface 
protein. In humans, the CD137 gene codes for a 255 aa protein with two 
potential N-linked glycosylation sites (Schwarz et al, 1997). This glycoprotein 
can exist as a 30kD monomer or a 55kD dimer (Kwon et al, 1994). There is 
60% sequence homology between the murine and human homologues of this 
gene. In the cytoplasmic domain, five regions are conserved between mouse 
and man suggesting that these regions might be important for the proper 
functioning of the CD137 protein. Besides its expression as a receptor, 
differential splicing of the gene can result in the production of a soluble form 
of CD137 that is secreted into the extracellular environment (Setareh et al, 
1995; Michel et al, 1998).  
 
1.1.2 Expression of CD137 and its role in immunity 
CD137 has been shown to be expressed on a number of immune cells. These 
include T lymphocytes, monocytes, dendritic cells (DCs), follicular dendritic 
cells (FDC), NK and NKT cells (Pollok et al, 1993; Schwarz et al, 1995; 
Melero et al, 1998; Kienzle and von Kempis, 2000; Futagawa et al, 2002; 
Pauly et al, 2002; Wilcox et al, 2002; Lindstedt et al, 2003; Choi et al; 2004). 
Expression of CD137 on these primary cells, except for monocytes and FDCs, 




expressed constitutively (Kienzle and von Kempis, 2000; Pauly et al, 2002; 
Lindstedt et al, 2003).  
The expression of CD137 on diverse immune cells also reflects the various 
roles that CD137 has on immunity. Even so, most of the research on CD137 
biology has focused on its activities on T cells which will be discussed in the 
next section. Studies on the role of CD137 on the innate immune system have 
been limited but these studies show that stimulation through CD137 promotes 
a pro-inflammatory state (Vinay and Kwon, 2011). 
On monocytes and DCs, CD137 activation induces pro-inflammatory cytokine 
production (Kienzle and von Kempis, 2000; Futagawa et al, 2002) while its 
expression on FDCs may help to co-stimulate B cell activation (Pauly et al, 
2002). CD137 stimulation has also been shown to induce proliferation of NK 
cells and their production of IFN- without increasing the cytolytic potential 
of these cells. Rather, CD137 activated NK cells seem to be important in 
enhancing cytolytic potential of CD8 T cells (Melero et al, 1998; Wilcox et al, 
2002). These studies show that CD137 stimulation affects the immune 
regulatory function of NK cells and that CD137 is important in mediating 
cross talk between the innate and adaptive immune responses. 
Apart from immune cells, CD137 expression has been reported on other cell 
types. Drenkard et al have reported that CD137 is expressed on blood vessel 
walls at sites of inflammation where CD137 is thought to facilitate the 
extravasation of monocytes into the inflammatory tissues (Drenkard et al, 
2007). Further, expression of CD137 has also been reported on neurons and 




with fibroblast growth factor 2 (FGF-2) (Reali et al, 2003). Chondrocytes too 
express CD137 in the presence of pro-inflammatory cytokines (von Kempis et 
al, 1997).  
CD137 expression has also been reported in several cancers such as in Reed-
Sternberg cells in Hodgkin’s lymphoma, rhabdomyosarcoma (personal 
communication, Schwarz H.) and osteosarcoma (Lisignoli et al, 1998). 
 
1.1.3 CD137 and T cell responses 
Since the discovery of CD137, most of the research on CD137 biology has 
focused on its activities in T cells. T cells are critical in mediating effective 
adaptive immune responses. These cells require two types of signals to 
function effectively. One important set of signal is received through the T cell 
receptor (TCR) that recognizes specific peptide-MHC complex. The second 
signal is usually mediated through co-stimulatory molecules. CD137 is one 
such co-stimulatory molecule. CD137 expression on T cells is strictly 
activation dependent and has been shown to provide co-stimulatory signals to 
both CD4+ and CD8+ T cells, resulting in proliferation and cytokine 
production (Pollok et al, 1993; Alderson et al, 1993; Hurtado et al, 1995). 
Further, CD137 has been shown to inhibit activation induced cell death 
(AICD) during restimulation of activated T cells by up-regulation of the anti-
apoptotic protein, Bcl-xL (Hurtado et al, 1997; Starck et al, 2005).  
Within the T cell population, most of the studies on CD137 co-stimulation 




preferentially promote proliferation and survival of CD8 T cells as compared 
to CD4 T cells. In CD8 T cells, the ability of CD137 to increase the 
expression of anti-apoptotic proteins, Bcl-xL and Bfl-1 contributes to the 
increased survival of these cells (Lee et al, 2002; Laderach et al, 2002). 
CD137 activation also leads to production of large amounts of interferon 
(IFN) -and tumour necrosis factor (TNF) which eventually translates to an 
enhanced cytolytic activity of the CD8 T cells (Shuford et al, 1997; Mittler et 
al, 1999). The ability of CD137 co-stimulation to enhance CD8 cytolytic T 
cell (CTL) activity has generated much interest in the possible use of agonistic 
anti-CD137 monoclonal antibodies in tumour immunotherapy. This will be 
further discussed in the next section. 
Studies in CD4 T cells have been limited and contradictory. Some studies 
showed that engagement of CD137 on naïve CD4 T cells promotes interleukin 
(IL) -2 production and proliferation and suppresses cell death (Gramaglia et 
al, 2000; Cannons et al, 2001). However, in a graft versus host disease model, 
CD4 T cells were reported to undergo AICD upon CD137 stimulation (Kim et 
al, 2004). Studies by Mittler et al further showed that anti-CD137 antibody 
may promote anergy of CD4 T cells resulting in the suppression of humoral 
immune responses towards sheep red blood cells (SRBC) in mice immunized 
against the SRBC antigen (Mittler et al, 1999). Further discrepancies are 
reported in CD4+CD25+ regulatory T cells (Tregs). A study by Choi et al, 
showed that CD137 inhibits the suppressive functions of Tregs and is 
therefore immunostimulatory in nature (Choi et al, 2004) but another study 
showed that CD137 co-stimulation induces proliferation of Tregs both in vitro 




other T cells (Zheng et al, 2004). The reasons behind these differences have 
yet to be resolved. However, most studies agree that CD137 generally does 
have a stimulatory role on the immune system and suppressive functions were 
mainly limited to CD4 T cells. This dual role of immune stimulation and 
immune suppression by CD137 may explain the ability of anti-CD137 
antibodies to eradicate tumours and to suppress autoimmune diseases. This 
dual role of CD137 will be further discussed in the next section. 
Studies which compared co-stimulation provided by CD137 to that provided 
by CD28, a critical co-stimulatory molecule on T cells, showed that CD137 
co-stimulation is independent of CD28. T cells from CD28 deficient mice 
could proliferate and produce IL-2 in response to B cell lymphomas bearing 
the CD137L (DeBenedette et al, 1997; Saoulli et al, 1998). In humans, 
CD137 activation of CD28- T cells induced proliferation, production of 
inflammatory cytokines and enhanced cytolytic activity (Bukczynski et al, 
2003).    
Even so, CD28 and CD137 can function synergistically to amplify T cell 
responses. CD28 and CD137 have been shown to synergize in the induction of 
IL-2 by T cells and to promote T cell survival and proliferation (Maus et al, 
2002; Wen et al, 2002). Studies in CD28 and CD137 deficient mice show that 
CD28 is important in the initial amplification of T cells while CD137 signals 
are important in maintaining survival and responsiveness of T cells later in the 
course of an immunological response (Bertram et al, 2002). Several studies 
have looked at the synergistic effects of CD28 and CD137 and show that 
activation of these two molecules enhanced T helper (Th) 1 responses. Hence 




may have implications for the therapeutic potential of CD137 (Kim et al, 
1998; Li et al, 2003;Zhong et al, 2010; Tammana et al, 2010).  
 
1.1.4 Immunotherapeutic potential of CD137 
1.1.4.1 CD137 and tumour immunotherapy 
CD137 signalling has been described to promote Th1 responses resulting in 
increased production of IFN- and TNF as well as enhanced CTL responses. It 
is not surprising then that CD137 agonists have generated much interest for 
the development of treatments against tumours. 
Consistent with in vitro findings, several studies in murine tumour models 
have shown that administration of agonistic anti-CD137 antibodies resulted in 
marked augmentation of tumour specific CD8 T cells responses, leading to the 
regression of well-established tumours (Melero et al, 1997; Miller et al, 2002; 
Wilcox et al, 2002). In a study by Melero et al, administration of anti-CD137 
antibodies prevented the development of tumours in a sarcoma and 
mastocytoma model while all mice treated with control antibodies developed 
tumours. CD137 stimulation could also result in the regression of large, 
vascularised tumours and these mice remained tumour free (Melero et al, 
1997).  
In an in vivo setting, CD137 seems to be important in eradicating tumours 
once the tumour has been established. Activated, tumour specific T cells 
would then express CD137 and systemically administered anti-CD137 




activity and therapeutic potential of the cells. This was supported by studies 
which showed that administration of antibodies late in the tumour model was 
more beneficial than early initiation of anti-CD137 treatment (Miller et al, 
2002). Further, in poorly immunogenic tumour models, administration of 
tumour antigens was shown to synergise with anti-CD137 antibodies in 
eradicating tumours, suggesting the importance of activation of T cells by 
tumour antigens, before activation of CD137 can be an effective tool in 
tumour immunotherapy (Wilcox et al, 2002; Ito et al, 2004; Li et al, 2007).    
To date, fully human CD137 specific antibodies have been developed for 
clinical trials (Lynch, 2008). However, the studies so far have been 
unsuccessful due to side effects observed in patients. Most of the studies on 
CD137 based tumour immunotherapy now focus on combinatorial therapy 
using anti-CD137 antibodies and other immune activating antibodies such as 
anti-CD28 and neutralizing anti-CTLA-4 antibodies (Tammana et al, 2010). 
Other studies are concerned with development of recombinant proteins that 
can target CD137 (Schabowsky et al, 2009; Zhong et al, 2010). It is hoped 
that with these recombinant proteins deleterious effects of using antibodies in 
humans can be overcome and a more effective CD137 tumour immunotherapy 
can be developed. 
 
1.1.4.2 CD137 and autoimmune diseases 
CD137 has mainly been described to be co-stimulatory to T cells, hence its 
development as a target in tumour immunotherapy. It would be expected then 




the reverse has been reported. The very same agonistic antibodies that can 
eradicate established tumours can also inhibit autoimmune responses.  
CD137 and its therapeutic effects in a number of autoimmune diseases have 
been documented. These include the ability of agonistic anti-CD137 
antibodies to treat systemic lupus erythematosus (SLE), inflammatory bowel 
diseases, collagen induced arthritis (CIA) and experimental autoimmune 
uveoretinitis (EAU) in mice models (Sun et al, 2002; Foell et al, 2003; Foell 
et al, 2004; Seo et al, 2004; Lee et al, 2005; Choi et al, 2006).  
In two different SLE models, the lupus prone NZB / NZW mice and MRL / 
lpr mice, administration of anti-CD137 antibody reverses acute disease, block 
chronic disease and prolong survival of the mice. The improvement of disease 
state can be attributed to the decline in the serum anti-dsDNA autoantibodies 
in the absence of continuous CD4 T cell help (Sun et al, 2002; Foell et al, 
2003). In CIA too, administration of anti-CD137 antibodies has been shown 
to prevent development of antibodies against collagen II and block disease 
development. CD137 based treatment can induce protective memory and the 
mouse models remained resistant to subsequent challenges with pathogenic 
antigen (Foell et al, 2004; Seo et al, 2004). Similar inhibition of disease 
development was also reported in a model for EAU (Choi et al, 2006). 
The mechanism by which CD137 inhibits autoimmune diseases is not well 
understood. The authors suggested that the anti-CD137 antibodies function by 
suppressing CD4 T cell dependent humoral immunity. Anti-CD137 antibodies 
could induce CD4 T cell anergy during its priming at the DC interface and 




development of autoantibodies (Foell et al, 2003; Foell et al, 2004; Mittler et 
al, 2004). Another possible mechanism that has been proposed is that anti-
CD137 antibodies induce expansion of antigen specific CD11c+CD8+ T cells 
which produce IFN- that suppress CD4 T cells through the accumulation of 
indoleamine 2,3-dioxygenase (IDO). Indeed the neutralization of IFN- or 
IDO reversed CD137 mediated inhibition of autoimmune disease 
development. This suggested that CD137 induced the suppression of antigen 
specific CD4 T cells in an IDO dependent mechanism (Seo et al, 2004, Choi 
et al, 2006).  
While studying the possible therapeutic potential of CD137, it was revealed 
that CD137 activation could both enhance and suppress immune responses. 
How could CD137 have a dual role in regulating the immune system? The 
answer seems to lie in the type of immune response initiated during the 
disease state. The CD137 tumour immunotherapeutic potential lies in its 
ability to enhance immune responses by CD8 T cells while its role in 
eradicating autoimmune diseases lies in its ability to suppress CD4 mediated 
responses. Thus, CD137 agonists can be used when the disease state requires 
CD8 enhancement or CD4 suppression for improvement of disease and not 
otherwise. Indeed, it was shown that administration of a CD137 agonist to a 
type I diabetes model, a CD8 T cell mediated autoimmune disease, led to the 
exacerbation of the disease state (Sytwu et al, 2003). Thus, understanding the 
underlying immunological response is important in determining whether 




Figure 1. Dual role of CD137 in immunotherapy. (Adopted from Sun et 
al, 2004). CD137 agonists can enhance CD8 T cell responses resulting in 
increased survival of CTL and IFN- production. This allows for the use of 
CD137 agonists in rejection of tumours, viruses and allografts. CD137 
agonists can also inhibit CD4 T cell responses by inducing CD4 T cell anergy 
or CD4 T cell apoptosis. This feature of CD137 is beneficial in eradicating 
CD4 T cell mediated autoimmune diseases.  
 
 
1.2 The CD137 ligand biology 
1.2.1 The CD137 ligand 
The ligand to CD137, CD137L, was identified by its binding to the soluble 
form of the CD137 protein that was fused to the Fc portion of human IgG1. In 
mouse, CD137L maps to chromosome 17 while the human counterpart was 
mapped to chromosome 19p13. In both species, the gene is made up of three 
exons and two introns and it encodes for a 254 aa and 309 aa protein in man 
and mouse, respectively (Goodwin et al, 1993; Alderson et al, 1994, Vinay 




transmembrane glycoprotein and has been identified to be part of the TNF 
superfamily (Armitage, 1994). Similar to CD137, the human and murine 
CD137L are related. However, only 36% sequence homology between the 
proteins of the two species was observed (Alderson et al, 1994), suggesting 
that the human and murine CD137L are poorly conserved. This also raises the 
possibility of an alternative ligand with a higher degree of conservation 
between man and mouse and possibly greater binding to the receptor. More 
recently, Kang et al, showed that CD137L can interact with various toll-like 
receptors (TLRs) including TLR3, TLR4 and TLR9 in murine macrophages, 
to mediate production of pro-inflammatory cytokines. In this case, interaction 
of CD137L seems to be independent of its receptor but depends on TLR 
agonists (Kang et al, 2007). Independent interaction from the receptor further 
suggests the possibility of an alternative ligand. However, the identity of this 
alternative ligand has yet to be determined.  
 
1.2.2 Reverse signalling in the TNF superfamily 
Most ligands of the TNF superfamily can be expressed as both a soluble 
protein and a transmembrane protein. Several reports have described receptor-
like properties of membrane bound ligands of the TNF superfamily including 
that of membrane bound TNF, CD40 ligand (CD40L), CD95 ligand (CD95L), 
OX40 ligand (OX40L) and CD30 ligand (CD30L). Signals through these 
ligands have generally been described to be co-stimulatory to T cells. This 
signalling through the ligand upon receptor ligand interaction has been termed 




communication in cell-to-cell signalling allowing for fine-tuning of cellular 
and functional interactions. Since members of the TNF / TNFR superfamily 
are mainly expressed by cells of the immune system, reverse signalling can 
enhance plasticity of the immune system as it makes stimulus and effect co-
dependent (Eissner et al, 2004).  
Among the TNFR / TNF superfamily, bidirectional signalling has been most 
well studied in the CD137 / CD137L system. Bidirectional signalling refers to 
initiation of signal transduction through both the CD137 receptor and its 
ligand upon receptor and ligand crosslinking. In the previous sections CD137 
signalling was shown to be activating to T cells while CD137L activation has 
been described to be activating to antigen presenting cells (APCs). Therefore, 
interaction between receptor and ligand can amplify ongoing immune 
responses (Schwarz 2005). The next sections describe expression and 







Figure 2. Bidirectional signalling in CD137 / CD137L system. Interaction 
between CD137 and CD137L on T cells and APCs can result in signalling 
through both receptor and ligand bearing cells leading to T cell co-stimulation 






1.2.3 Expression of CD137L  
CD137L has mainly been shown to be expressed on APCs, i.e. B cells, DCs 
and monocytes. Apart from APCs, T cells too can express CD137L.  
Among the APCs, monocytes and macrophages have been shown to express 
CD137L constitutively (Pollok et al, 1994; Ju et al, 2003). However, 
expression has been described to be low and up-regulation of ligand 
expression is observed after further stimulation with lipopolysaccharide (LPS) 
(Futagawa et al, 2002; Laderach et al, 2003). On DCs too CD137L expression 
is low and up-regulated when cells were matured with pro-inflammatory 
stimuli such as IL-1, LPS or anti-CD40 antibodies (Futagawa et al, 2002; 
Laderach et al, 2003). CD137L expression has also been detected on B cells. 
Its expression on B cell lines is constitutive while expression on primary B 
cells seems to be inducible (Pollok et al, 1994, Zhou et al, 1995; DeBenedette 
et al, 1997; Palma et al, 2004).  
Apart from APCs, T cells have been reported to express CD137L but at a 
much lower level than in B cells (Zhou et al, 1995). In primary T cells, 
expression of CD137L is strictly activation dependent (Polte et al, 2007).  
 
1.2.4 Biological activities of CD137L signalling 
1.2.4.1 CD137L stimulation and its role in myelopoiesis 
CD137L expression has been detected on long term and short term 
hematopoietic stem cells, multipotent progenitors, common lymphoid 




progenitors (Lee et al, 2008; Jiang et al, 2008(a)). It is not surprising then that 
CD137L signalling can regulate haematopoiesis. In vitro studies with murine 
and human progenitor cells showed that recombinant CD137 protein induced 
proliferation and myeloid colony formation which is followed by monocyte 
and macrophage differentiation (Jiang et al, 2008(a); Jiang  et al, 2008(b)). 
This suggested that CD137L signalling supports myelopoiesis.  
However, in in vivo studies, it was concluded that CD137 negatively regulates 
myelopoiesis. An increased number of myeloid progenitors was found in both 
CD137 and CD137L deficient mice. Further, competitive repopulation 
experiments between wild type and receptor-deficient bone marrow cells or 
between wild type and ligand deficient cells in irradiated wild type mice 
showed preferential repopulation by cells from receptor or ligand deficient 
mice (Lee et al, 2008). This clearly showed that the CD137 / CD137L system 
is involved in suppressing myelopoiesis. The reason behind such 
discrepancies between the in vivo and in vitro system is unclear. However, it 
may be possible that differences are due to the physiological state of the cells. 
In the in vivo studies, mice were in steady state where CD137 expression is 
low. Under steady state conditions, CD137 may function to negatively 
regulate generation of monocyte or macrophages as it is not necessary to have 
high numbers of myeloid cells. Conversely, in the event of an infection high 
CD137 expression would be induced that may promote myelopoiesis to 






1.2.4.2 Effects of CD137L stimulation in monocytes 
Studies have shown that the activation of CD137L on monocytes induces 
production of pro-inflammatory cytokines: IL-8, IL-6 and TNF (Langstein et 
al, 1998; Langstein et al, 2000; Sollner et al, 2007) and a down-regulation of 
IL-10, a cytokine associated with monocyte deactivation (Langstein et al, 
1998). The cytokine profile of CD137L activated monocytes suggests that 
CD137L signalling primes monocytes for activation by regulating the 
inflammatory cascade. Further, cross-linking of CD137L has been shown to 
induce adherence of peripheral monocytes. Adhesion of the monocytes is 
accompanied by morphological changes that are characterized by three basic 
morphologies: elongated, branched and rounded (Langstein and Schwarz, 
1999; Sollner et al, 2007). All in all, these data suggest that CD137L 
stimulation activates peripheral monocytes. 
Apart from being an activating factor, CD137L activation enhanced monocyte 
survival, proliferation and endomitosis. Primary peripheral monocytes that 
were treated with CD137 showed an ability to survive even after twelve days 
of culture while untreated monocytes could only survive for up to 6 days post 
isolation (Langstein and Schwarz, 1999). Survival of monocytes seems to be 
mediated by monocyte colony stimulating factor (M-CSF), granulocyte 
macrophage colony stimulating factor (GM-CSF) and IL-3 produced upon 
CD137L ligation. Of all these factors, M-CSF plays the most important role in 
inducing survival as neutralization of the induced M-CSF significantly 
decreased survival of cultured monocytes (Langstein and Schwarz, 1999). 
Proliferation in response to CD137L activation is also mediated by M-CSF 




proliferation sets CD137 apart from other monocyte growth factors. Studies 
have shown that although these two factors are essential for proliferation, they 
are not sufficient and other unidentified factors which are induced by CD137L 
activation are required for monocyte proliferation (Langstein et al, 1999).  
The same activating effects of CD137L signalling have been reported in the 
murine system. Bone marrow derived macrophages treated with recombinant 
CD137 protein showed enhanced adherence and increased expression of pro-
inflammatory factors intercellular adhesion molecule-1 (ICAM-1), IL-1, IL-
6 and M-CSF. In a murine macrophage cell line too, CD137L activation 
increased adherence and proliferation (Kim et al, 2009). Hence, effects of 
CD137L activation are comparable between different species.   
Apart from acting alone, CD137 can act with other pro-inflammatory factors 
to potentiate an inflammatory response. Treatment of monocytes with CD137 
and CD40 ligand induced IL-12 production (Laderach et al, 2003) and CD137 
can further increase IL-8 and sustain TNF production by LPS (Langstein et al, 
2000). This synergistic effect with LPS may be mediated by both CD137 
dependent and independent signalling through CD137L as studies have shown 
that CD137L can interact with TLR4, a receptor to LPS (Kang et al, 2007). 
Hence, CD137L signals can be integrated with signals from other 
inflammatory stimuli during inflammation.   
More recently, several evidences point towards the involvement of CD137L 
activation in monocyte extravasation. CD137 has been reported to be 
expressed on blood vessel walls at sites of inflammation and on endothelial 




CD137 expressed on activated endothelial cells can enhance ICAM-1 and 
lymphocyte function-associated antigen 1 (LFA-1) mediated adhesion of 
monocytes and this may promote monocyte extravasation (Quek et al, 2010). 
Indeed, greater monocyte infiltration was reported in CD137 coated matrigel 
that had been inserted in the flank of mice as compared to control matrigel 
(Drenkard et al, 2007). Put together, the data suggest that CD137L signalling, 
can promote monocyte extravasation into inflammatory tissues.  
Many of these studies on CD137L signalling have established, without doubt, 
that CD137L stimulation activates monocytes. However, more studies need to 
be done to more closely determine how monocyte functions and 
differentiation are affected by CD137. This may provide an insight as to how 
CD137L signalling in monocytes can influence the bigger immunological 
network.   
 
1.2.4.3 Effects of CD137L stimulation in B cells and DCs 
Unlike studies on CD137L activation in monocytes, studies on effects of 
CD137L stimulation in B cells and DC are less extensive. Nonetheless, 
CD137L signalling has been shown to be activating to both types of APCs.  
B cells have been reported to express CD137L only upon activation. It is not 
surprising then that CD137L signalling does not activate resting B cells. 
Rather, activation of CD137L induces proliferation and immunoglobulin 
synthesis of pre-activated B cells (Pauly et al, 2002). Under physiological 




of B cells in the germinal centres. Studies have shown that FDCs which 
interact closely with B cells to build up an effective humoral response express 
CD137. This suggests that the CD137 receptor / ligand system may mediate 
co-stimulation of B cells by FDC during affinity maturation (Pauly et al, 
2002; Lindstedt et al, 2003). Further evidence on the role of CD137L 
stimulation  in B cell development in germinal centres comes from studies in 
CD137L deficient mice. In this study, CD137L deficient mice were 
predisposed to development of B cell lymphomas originating from germinal 
centres (Middendorp et al, 2009). Conversely, in a transgenic mice model that 
express CD137L constitutively on APCs, a depletion of peripheral B cells was 
observed (Zhu et al, 2001). Put together, it seems that CD137L signalling is 
critical in controlling proper B cell differentiation and activation (Shao and 
Schwarz, 2010). 
In DCs too, CD137L delivers activating and maturing signals. CD137L 
signalling increased adherence and expression of CD11c, CD80, CD86, and 
MHC class II (Kim et al, 2002). It also induces secretion of pro-inflammatory 
cytokines IL-6, IL-12 and TNF (Futagawa et al, 2002; Laderach et al, 2003, 
Lippert et al, 2008). Studies by Lippert et al showed that CD137L mediated 
DC maturation is dependent on TNF that was produced during CD137L 
stimulation. Addition of anti-TNF neutralizing antibodies abrogated DC 
maturation. These DC matured with CD137 treatment were functional and 
could produce IL-12 and induce T cell proliferation and production of IFN- 
in an antigen specific mixed lymphocyte reaction (MLR) (Lippert et al, 2008). 
Such activating profiles on APCs strongly indicate that CD137L stimulation 




1.2.4.4 Effects of CD137L stimulation in T cells 
CD137L signals in APCs and CD137 signals through T cells are stimulatory 
in nature. However, CD137L activation in T cells seems to be inhibitory. 
Earlier studies by Schwarz et al showed that CD137 expressing chinese 
hamster ovary (CHO) cells inhibited proliferation of anti-CD3 stimulated 
peripheral blood mononuclear cells (PBMCs). Cell cycle analysis confirmed 
that a decrease in lymphocytes in the S-phase was observed with CD137 
treatment (Schwarz et al, 1996). Inhibition of T cell proliferation is 
accompanied by apoptosis that is independent of CD95, a well characterized 
death inducing receptor (Michel et al, 1999). More recently, Ju et al also 
reported that treatment of T cells with anti-CD3 and anti-CD137L antibodies 
inhibited T cell proliferation.  
Despite these studies, limited research has been done to determine the 
mechanism by which T cell inhibition is achieved. One study by Polte et al 
provided evidence that CD137L mediated T cell inhibition was mediated by 
other CD137L expressing cells. In this study, the administration of agonistic 
anti-CD137L antibodies prevented development of asthma-like phenotype. 
CD137 ligand activation was shown to be inhibitory towards CD4 T cells 
while inducing IFN- production by CD8 T cells. Abrogation of the asthma 
phenotype was dependent on this IFN-production by CD137L stimulated 
CD8 T cells (Polte et al, 2007). Apart from this study, not much else is known 






1.2.5 CD137L signal transduction 
Despite the many reports on the biological activities associated with CD137L 
signalling, not much is known about the signal transduction pathway upon 
CD137L activation. The limited studies on CD137L signalling have shown 
that this signalling is in essence similar to signalling through classical 
receptors and utilizing the same signal transduction molecules. 
In peripheral monocytes and the human monocytic cell line, THP-1, signalling 
through CD137L was shown to be mediated by protein tyrosine kinases; p38 
mitogen associated protein kinase (MAPK), extracellular signal regulated 
kinase (ERK) 1/2, phosphoinositide 3-kinase (PI3K) and protein kinase A 
(PKA) (Sollner et al, 2007). However, another study by Saito et al, showed 
that CD137L signalling in the murine macrophage cell line, RAW264.7, did 
not affect phosphorylation of inhibitor of B (IB), ERK1/2, p38MAPK and 
c-Jun N-terminal kinase (JNK). It was shown to affect protein kinase B (Akt), 
the downstream target of PI3K (Saito et al, 2004). A more recent study further 
showed that in RAW264.7 cells, viability induced by CD137L activation is 
mediated by Src tyrosine kinase, mammalian target of rapamycin (mTOR) and 
PI3K, followed by phosphorylation of Akt and p70S6 kinase (Kim et al, 
2009). This difference in signal transduction molecules identified in the 
former study as compared to the latter two studies may be attributed to the 
difference in cell type as well as species from which the cells were derived.  
Apart from these studies, not much more is known about the signal 




should be performed to map out the signal transduction pathway involved in 
CD137L signalling.  
 
1.3 Immune responses in CD137 / CD137L deficient mice 
Both CD137 and CD137L deficient mice have been generated to study the 
effects of CD137 and CD137L activation in vivo and have generated much 
insight into the activities of the CD137 / CD137L system. These gene 
deficient mice developed normally and showed no apparent defects in T and B 
cell and lymphoid development and are fully fertile (DeBenette et al, 1999; 
Kwon et al, 2002). However, deficiencies in immune responses are observed 
in these mice upon infection or inflammation. This is not surprising since 
CD137 expression is regulated and activation dependent in most cells in 
which it is expressed on.  
Studies in both CD137 and CD137L deficient mice supported in vitro 
observations that CD137 signals preferentially co-stimulate CD8 T cells as 
compared to CD4 T cells and are important in mounting CD8 anti-tumour or 
anti-viral responses. CD137L deficient mice are capable of mounting as 
effective a humoral responses as wild type mice but have impaired CTL 
responses to influenza virus, decreased IFN- production in response to 
lymphocytic choriomeningitis virus (LCMV) and decreased CD8 T cell 
expansion (DeBenedette et al, 1999; Tan et al, 1999). As expected, CD4 T 
cell responses were minimally affected by the absence of CD137L in the 
presence of LCMV infection (Tan et al, 1999). In CD137 deficient mice too, 




enhanced T cell proliferation in response to mitogens (Kwon et al, 2002). 
Since the CD137 / CD137L system has been shown to exhibit bi-directional 
signalling, the enhanced T cell proliferation in the absence of CD137 may be 
a consequence of the absence of signals through the CD137L. Indeed, as 
mentioned in section 1.2.4.4, CD137L stimulation has been shown to inhibit T 
cell proliferation and to induce T cell apoptosis in vitro. Further studies on 
CD4 T cells in the absence of CD137 showed enhanced CD4 T cell 
proliferation and effector CD4 T cell responses to specific antigen (Lee et al, 
2005). Again, it is unclear if the observed effects were mediated by CD137 or 
CD137L signals.  
Apart from its expression on T cells, CD137 and especially CD137L have 
been reported to be expressed on APCs. Effects of absence of CD137 or 
CD137L on the innate immune system have not been well documented but the 
CD137 receptor-ligand system does affect the innate immune cells. A study 
by Lee et al, reported that neutrophils from CD137-deficient mice were 
defective in generating reactive oxygen species (ROS) and showed a 
decreased phagocytic potential in response to Listeria monocytogenes 
infection (Lee et al, 2005). Since CD137 is expressed on neutrophils, this 
finding suggests that CD137 may have a role in neutrophil activation. Another 
study in CD137L-deficient mice showed development of B cell lymphoma in 
germinal centres, suggesting an involvement of CD137 in B cell 
differentiation and activation (Middendorp et al, 2009). Apart from B cell 
development, CD137 and CD137L have been shown to be involved in 
myeloid cell development. As mentioned in section 1.2.4.1, under steady state 




myeloid cell numbers with subsequent accumulation of DCs in peripheral 
organs, suggesting that CD137 / CD137L are involved in negatively 
regulating myeloid development and differentiation (Kwon et al, 2002; Lee et 
al, 2008). However, this is in contrast to in vitro experiments where it was 
shown that CD137L activation enhances myeloid cell and macrophage 
development (Jiang et al, 2008(a)). The reasons for these discrepancies is 
unknown but may be attributed to the steady state of the animals versus the 
high concentration of CD137 protein used in the in vitro cultures which 
mimics an inflammatory state. 
So far these gene deficient mice have been useful in elucidating the possible 
functions of CD137 and its ligand. However, discrepancies between in vivo 
and in vitro data do exist. Due to the bi-directional signalling nature of the 
CD137 receptor ligand pair, it is difficult to separate responses elicited by the 
receptor from those elicited by the ligand. These responses in gene deficient 
mice reflect the complex nature of CD137 and CD137L activation and more 
studies need to be done to separate biological activities of CD137 from those 
of its ligand. 
 
1.4 Myeloid cells, its differentiation and function 
Myeloid cells represent a population of immune effector cells which are 
derived from the common myeloid progenitor and constitute part of the innate 
immune system. One of the major components of the myeloid cell population 
is the monocytes. Monocytes circulate in blood and continually migrate into 




its micro-environmental signals. The following sections describe the different 
classifications of macrophages and DCs, and their function and interactions 
with other immune cells, particularly with T cells.  
 
1.4.1 Macrophage classifications and functions 
Macrophages are mainly found in peripheral tissues and are important effector 
cells of the innate immune system, protecting against pathogenic invasion. 
However, macrophages play more than just a pro-inflammatory role. 
Macrophages also have a part to play in development, maintaining 
homeostasis by clearance of apoptotic cells and scavenging of toxic 
compounds. Macrophages continually survey their environment and can 
develop different phenotypes depending on the signals that they receive. Thus, 
these cells have been described to have incredible plasticity and can be 
broadly classified as the classically activated and the alternatively activated 
macrophages that are designated as M1 and M2, respectively (Gordon, 2003; 
Martinez et al, 2008). 
M1 macrophages are defined as having strong anti-microbial properties and 
promote strong IL-12 mediated Th1 responses (Verreck et al, 2004). These 
macrophages are generally regarded to be pro-inflammatory in nature and are 
activated in the presence of pro-inflammatory factors such as IFN-TNF and 
microbial proteins such as LPS. These macrophages are primed to secrete pro-
inflammatory cytokines and increase superoxide anions and oxygen and 




et al, 2001). Thus, M1 macrophages have an important role to play in host 
defences as well as promotion of anti-tumour activities.  
Unlike M1 macrophages, M2 macrophages are involved in maintaining 
homeostasis. M2 macrophages are more diverse than M1 macrophages and 
can be further classified into M2a, M2b and M2c depending on the stimulus 
which initiates the differentiation. M2a describes IL-4 or IL-13 stimulated 
macrophages, M2b describes macrophages activated by immune complexes 
and TLR ligands while M2c represent IL-10 stimulated macrophages 
(Anderson et al, 2002; Van Ginderachter et al, 2006). Despite these different 
sub-classifications within the M2 macrophage population, these macrophages 
generally promote Th2 responses, have reduced pro-inflammatory cytokine 
secretion but enhanced production of anti-inflammatory molecules such as IL-
10 and transforming growth factor (TGF) - (Anderson et al, 2002; Noel et al, 
2004). Hence, M2 macrophages protect against detrimental immune responses 
and are involved in resolution of infections. These macrophages have also 
been implicated in promoting tissue remodelling and wound healing (Kodelja 
et al, 1997; Song et al, 2000). However, in tumour environments, 
macrophages can be stimulated to adopt an M2 type phenotype that is 
beneficial for tumour survival and growth (Mantovani et al, 2002). These 
macrophages have been specifically termed tumour-associated macrophages 
(TAMs). 
Various markers have been used to distinguish the two main types of 
macrophages. These include the cytokine patterns of the macrophages i.e. 




and low IL-12 production by M2 macrophages, arginine metabolism and gene 
markers such as FIZZ1 and Ym(1/2) (Munder et al, 1998; Mantovani et al, 
2004; Ghassabeh et al, 2006). Despite these markers, it is difficult to identify 
specific macrophage phenotypes as macrophages exhibit great plasticity and 
one macrophage can express both M1 and M2 markers. Mosser and Edwards 
therefore suggested that macrophage population should be classified 
according to the fundamental macrophage function of host defence, wound 
healing and immune regulation. These three basic macrophage populations are 
proposed to be analogous to the three primary colours in a colour wheel and 
macrophages can evolve to exhibit characteristics that are shared by more than 
one macrophage population, just like the blending of colours on a colour 
wheel (Mosser and Edwards, 2008). Difficulties in classifying these 
macrophages reflect their enormous heterogeneity and the many roles that 
they play in health and disease.  
 
1.4.2 Monocyte derived DCs  
DCs are the most potent APCs and have mainly been divided into the myeloid 
DCs and plasmacytoid DCs which arise from myeloid and lymphoid 
progenitors, respectively. Plasmacytoid DCs are a rare subset of DCs defined 
by the surface markers BDCA2, ILT7 and CD123 and produce large amounts 
of type 1IFN in response to virus infections (Colonna et al, 2004; Liu, 2005). 
Myeloid DCs, however, are more abundant and many different subsets of 
myeloid DCs have been described in different tissues including peripheral 




section mainly focuses on the myeloid DCs, specifically the monocyte derived 
DCs, and their activities. Blood monocytes are also the most commonly used 
precursor cells for generating human DCs in culture.   
Monocytes are known to differentiate to macrophages and DCs upon 
migration into tissues. Under steady state conditions, monocytes generally 
differentiate to macrophages while their differentiation to DCs seems to be 
restricted to the presence of inflammation (Fogg et al, 2006; Auffray et al, 
2009). Unlike macrophages, DCs can be further divided into two functional 
states, the immature and mature states. Immature DCs (imDCs) are well 
equipped to survey their environment and to capture and process antigens. 
These cells lack the accessory signals for T cell activation and are weak 
stimulators of T cells (Banchereau and Steinman, 1998). In the presence of 
pro-inflammatory signals however, DCs undergo maturation where extensive 
transformation occurs, including the down-regulation of antigen capturing 
potential and high expression of antigen–MHC complexes. Maturation is also 
accompanied by expression of a number of co-stimulatory molecules such as 
CD80 and CD86 (Caux et al, 1994) and release of cytokines and chemokines 
such as IL-12, IL-8 and macrophage inflammatory protein (MIP) -1 (Cella et 
al, 1996; Koch et al, 1996). These features of DCs allow them to effectively 
provide activating signals to T cells and mount an adaptive immune response 
(Banchereau and Steinman, 1998). These 2 functional states of DCs make 
them the most potent APC and also the only cell type that can activate naïve T 




Many subsets of DCs have been described in mice. These include CD4-CD8+, 
CD4+CD8- and CD4-CD8- DCs in the spleen (Vremec et al, 2000), CD4-CD8-
CD11b+ DCs in the lymph node and Langerhans cells in the skin (Henri et al, 
2001). Further, phenotypically different population of DCs have been reported 
in the interstitium of various organs. These DCs are defined by the expression 
of various markers including CD11c, CD8, CD11b and CD103 (Chirdo et al, 
2005). In humans however, DC subsets are not as well defined as in mice. 
Blood remains the most readily available source of DCs, for experimental 
purposes, in humans and various cytokine cocktails have been established to 
generate DCs from CD34+ precursors from cord blood and adult bone marrow 
or from peripheral blood monocytes (Young et al, 1995; Caux and 
Banchereau, 1996). However, whether these in vitro generated DCs have 
close resemblance to naturally occurring DC subtypes in humans is unclear.  
Despite the different DC and macrophage classifications and the different 
markers that have been identified for the different types of DCs or 
macrophages, it remains difficult to separate these two cell populations. This 
is largely due to the many phenotypic similarities that these cells have, 
including the expression of similar surface markers such as CD11c and F4/80 
and the requirement for similar growth factors such as M-CSF (MacDonald et 
al, 2005; Hume, 2008). Hume therefore argued that there are no markers that 
distinguish DCs from macrophages and that DC as a separate cell type do not 
actually exist. However, the general consensus is that DCs being the most 





1.4.3 DC immunotherapy and its challenges 
DCs are the most potent APCs that can influence T cell polarization, thus, 
initiating appropriate immune responses and inducing memory. This makes 
DCs an attractive tool for tumour immunotherapy whereby DCs from patients 
are isolated, activated and primed to induce appropriate T cell immune 
responses against the patients’ own tumours. Many studies on DC tumour 
immunotherapy have been conducted in mice with great success (Ardavin et 
al, 2004). Consequently, phase I/II clinical trials involving therapeutic DC 
based vaccines have been set up to treat a multitude of cancers including 
malignant melanoma, multiple myeloma, colorectal cancer and prostate 
cancer (Banchereau et al, 2001; Heiser et al, 2002; Reichardt et al, 2003; 
Morse et al, 2003). Despite these studies, DC based vaccines generally 
showed minimal clinical responses. This could be attributed to the highly 
immunosuppressive tumour environment which can impair tumour clearance 
even in the presence of tumour specific effector T cells and to the failure of 
tumour specific antigen T cell homing to the tumour site (Ilett et al, 2010). 
Other critical parameters that can influence the success of DC vaccines 
include the number of DCs isolated, maturation status and effector functions 
of generated DCs, antigen loading and route of DC delivery. Among these, the 
maturation status and effector functions will have the greatest impact on T cell 
polarization and subsequent anti-tumour responses. Various ex vivo DC 
generation protocols have been utilised. These include generation of DCs 
from CD34+ progenitor cells from bone marrow by culturing them in the 
presence of GM-CSF and TNF or IL-4 for two weeks (Tuyaerts et al, 2007). 




monocytes can be easily obtained from buffy coat preparations. Classical DCs 
can be generated from monocytes by culturing them in the presence of GM-
CSF and IL-4 or IL-13 for 5 to 7 days (Tuyaerts et al, 2007). Hence, 
generation of DCs from blood monocytes is also faster than when CD34+ 
progenitor cells were used. In fact, Dauer et al has reported that DCs can be 
generated from monocytes within 48h by culturing them in the presence of 
GM-CSF and IL-4 for 24 h followed by a further incubation with pro-
inflammatory mediators TNF, IL-1 and prostaglandin E2 (PGE2) for another 
24 h.  These cells were termed FastDCs and were shown to be effective in 
priming tumour antigen specific cytotoxic T cells (Dauer et al, 2005).  
Following generation of sufficient DCs, their maturation status would 
determine their immune-stimulatory potential. DC maturation is achieved by 
culturing imDCs in the presence of a variety of pro-inflammatory factors 
including CD40L, TNF and calcium ionophore (Osada et al, 2006) but the 
most widely used maturation stimulus consists of a combination of IL-1, IL-
6, TNF and PGE2 (Osada et al, 2006; Tuyaerts et al, 2007). Proper maturation 
would arm DCs with co-stimulatory molecules such as CD80 and CD86 that 
can induce T cell activation rather than T cell anergy. More than expression of 
these surface molecules which function as surrogate markers of their 
immunogenic potential, effector function of DCs would play a more critical 
role in ensuring effective anti-tumour T cell activity. The cytokine production 
profile of DCs can give a good gauge of T cell activation outcomes. Thus, 
DCs for use in tumour immunotherapy should typically produce high IL-12, 
IFN- and IL-6 while suppressing IL-10 production (Tuyaerts et al, 2007). 




that is important in mediating anti-tumour effects. Despite the efforts of 
developing DC vaccines with the desired effector profile, the tumour micro-
environment may eventually influence DCs to acquire an effector function 
which is beneficial to tumour growth which may explain the failure in the 
efficacy of DC vaccines in clinical settings.  
To date, there is no standard protocol for DC generation and maturation that is 
most effective for use in tumour immunotherapy. Studies are continually 
being done to optimally generate DCs in the shortest possible time and with 
desired effector functions. New proteins and growth factors should also be 
tested on their ability to induce DC differentiation.    
 
1.4.4 Interactions between T cells and myeloid cells 
1.4.4.1 T cell co-stimulation 
Induction of an appropriate adaptive immune response requires interaction 
between T cells and myeloid cells, especially DCs. Of course, the most 
recognized function of DCs would be to provide T cell co-stimulation for the 
activation of an adaptive immune response. DCs are also critical in 
influencing T cell differentiation through the production of cytokines. The 
most established T cell responses include those of Th1, Th2 and Th17. 
Cytokines produced by DCs in response to stimuli are critical inducers of Th 
subset development. It has been well established that each of these Th subsets 
can be identified through its trademark cytokine profile. Th1 cells have been 




initiate CTL responses and to eliminate intracellular pathogens. Th2 cells 
typically produce IL-4, IL-5 or IL-13 and are involved in defence against 
extracellular pathogens such as multicellular parasites while Th17 cells are 
defined by the production of IL-17 and are proposed to be involved in 
defences against extracellular bacteria and fungi (Kidd, 2003; Kadowaki, 
2007; Kurts, 2008). Apart from inducing pro-inflammatory responses, DCs 
can also induce Tregs which are immunosuppressive and function to prevent 
excessive inflammation. Similar to induction of the other T cell subsets, Treg 
differentiation is also dependent on DC cytokine production, specifically on 
the immunosuppressive cytokine TGF-This leads to activation of the 
transcription factor forkhead box P3 (FOXP3) in T cells that is both necessary 
and sufficient for Treg development and maintenance (Zheng and Rudensky, 
2007).   
Despite these clearly defined T cell subsets, T cell differentiation is more than 
just the simplistic one way differentiation towards a single Th subset. The 
helper subsets also cross-regulate each other so that the cytokine balance 
promote appropriate immune responses. Studies of Th17 cells and Tregs 
further indicate that T cell differentiation is more plastic than what was 
initially thought. Several studies have shown that committed Th17 cells can 
deviate to a Th1 type phenotype in response to IL-12 and a Th2 phenotype in 
response to IL-4 (Lexberg et al, 2008; Lee et al, 2009). Tregs too are shown 
to exhibit developmental plasticity under conditions of inflammatory cytokine 
stimulation. In the presence of IL-6, Tregs can be directed towards the Th17 
phenotype as characterized by the production of IL-17 and down-regulation of 




development during an immune response and the importance of myeloid cells 
in influencing T cell differentiation through the cytokines that they produce.  
1.4.4.2 Suppressive action on T cells 
Other than induction of T cell proliferation and differentiation, T cell 
interactions with myeloid cells have been shown to induce T cell apoptosis. 
Several studies show that T cell apoptosis can be mediated by activated 
monocytes and this was termed monocyte dependent T cell death (MDCD) 
(Wu et al, 1996; Oyaizu et al, 1997; Wesch et al, 1998). In some cases, 
MDCD seems to involve the CD95 death receptor. Activated monocytes were 
shown to up-regulate CD95L and T cell apoptosis was blocked upon addition 
of a CD95-Ig fusion protein (Wu et al, 1996; Oyaizu et al, 1997). In other 
cases, T cell apoptosis was independent of CD95. Many CD95 independent 
pathways have been proposed to be at play during MDCD. These include the 
involvement of ROS as MDCD could be inhibited by catalase (Wesch et al, 
1998). Others showed the possible involvement of IDO and HLA class II 
ligation (Munn et al, 1999; Lee and Molinaro, 2003). To date, no specific 
mechanism that mediates MDCD has been proposed. T cell apoptosis 
occurring late in an immune response is generally regarded to be important in 
the removal of activated T cells to prevent excessive inflammation after 
resolution of an infection. However, MDCD generally occurs early during the 
monocyte T cell interaction. As such, the physiological significance of 
MDCD is unclear.  
T cell activity can also be inhibited by the action of myeloid derived 




macrophages, granulocytes, DCs and immature myeloid cells (Boros et al, 
2010).  MDSC suppress T cell function by the action of inducible nitric oxide 
synthase (iNOS) and arginase 1 (Arg-1) (Rodriguez and Ochoa, 2008) leading 
to the production of NO and depletion of arginine. These two factors in turn 
induce T cell apoptosis and inhibit T cell proliferation and its responses 
(Rodriguez et al, 2007). Expansion of MDSC has especially been documented 
in the presence of tumours or in mice that developed spontaneous 
malignancies (Boros et al, 2010). More recently, much interest is focused on 
the therapeutic potential of MDSC in generating transplant tolerance.  
The ability of myeloid cells to influence both co-stimulation and inhibition of 
T cells is important in the regulation of immune responses. These interactions 
are important in the course of an inflammation as well as for the maintenance 
of T cell homeostasis. Of course in some pathologies the inflammatory micro-
environment can utilise interactions between myeloid cells and T cells to 
ensure propagation of disease state. This is most evident in the case of cancers 
whereby the tumour micro-environment supports the development of TAMs 
and MDSC which inhibit CTL functions leading to tumour survival and 
proliferation. As such, understanding factors that govern myeloid T cell 
interactions can allow the manipulation of immune responses for therapeutic 
purposes.  
 
1.5 Research objectives 
Studies on CD137L signalling in PBMCs and monocytes show that CD137L 




research on the mechanism by which CD137L signalling inhibits T cell 
proliferation and the functional effects of CD137L stimulation on monocytes 
is still lacking. Thus, this project aims to understand the mechanism(s) by 
which CD137L induces its inhibitory effects on T cells and to further 
characterize the effects of CD137L stimulation on monocytes and to evaluate 
the possible roles of CD137L activated monocytes in immune regulation. 
More specifically the project aims to determine: 
a) Inhibitory effects of CD137L signalling on PBMC subsets. CD137 
agonists have been shown to inhibit T cell proliferation and to induce 
apoptosis in PBMCs. However, it is unknown whether all PBMC 
subsets are equally affected and whether CD137L induced T cell 
inhibition is dependent on other PBMC subsets. Hence, CD137L 
induced T cell inhibition needs to be further characterized.  
b) Mechanism of CD137L induced T cell inhibition. CD137L 
stimulation has been shown to induce apoptosis in PBMCs. However, 
CD137L itself does not contain a death domain in its cytoplasmic 
region. Earlier studies have also shown that CD137L induced 
apoptosis is independent of CD95. Hence, the mechanism by which 
CD137L activation induces apoptosis is unclear. 
c) Effects of CD137L stimulation on monocyte functions. Earlier 
studies have shown that CD137L stimulation activates monocytes as 
indicated by the production of pro-inflammatory cytokines and 
morphological changes. No further studies have specifically looked at 




phagocytosis, oxidative burst and endocytosis. This project hopes to 
further characterize the effects of CD137L activation in monocytes. 
d) Effects of CD137L activation on monocyte differentiation. 
Monocytes are known to differentiate to macrophages or DCs 
depending on the micro-environmental signals that they receive. 
Therefore, it is of interest to determine if CD137L activation has any 
role to play in monocyte differentiation and the type of differentiation 
that it supports. 
e) Monocyte and T cell interactions upon CD137 treatment. 
Monocyte activation can influence T cell responses through the 
production of cytokines and their differentiation status. As such it 
would be useful to determine the consequences of interaction between 
CD137L activated monocytes and T cells. This may shed light on the 
role of CD137L stimulation in immune regulation during 
inflammation and may provide clues to possible therapeutic 
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2.1 Recombinant protein, antibodies and reagents 
Recombinant human CD137-Fc, a fusion protein consisting of the 
extracellular domain of human CD137 fused to the constant domain of human 
IgG1 (Fc), was purified from supernatants of stable transfected CHO cells by 
protein G sepharose, as described previously (Schwarz et al, 1996). Human 
IgG1 Fc protein was purchased from Chemicon International (Temecula, CA, 
USA). Recombinant human GM-CSF, M-CSF, IL-4, IFN- were purchased 
from Peprotech Inc. (New Jersey, USA). Recombinant LPS from E.coli was 
obtained from Sigma-Aldrich (St Louis, USA).  
The reagents catalase, calcium ionophore A23187 and phorbol myristate 
acetate (PMA) were purchased from Sigma-Aldrich (St Louis, USA). 
Antibodies purchased were used for the purpose of flow cytometric analysis, 
neutralization of protein of interest or activation of cells. All antibodies used 
recognise human antigens and are listed in Table 1. 
 
Table 1. List of antibodies 
Antigen Conjugate Clone Company 
CCR7 APC 3D12 eBioscience 
CD137L 
Unlabelled 41B436 Alexis biochemicals 
Unlabelled 5F4 Biolegend 
Unlabelled C65-485 BD Pharmingen 
CD14 PE 61D3 eBioscience 
CD1a PE HI149 BD Pharmingen 
CD20 PE B-Ly-1 Dako 
CD209 / DC-SIGN PE eB-h209 eBioscience 
CD25 PE 4E3 Miltenyi Biotech 
CD3 
Unlabelled OKT3 Purified from hybridoma supernatant 
PE OKT3 eBioscience 
APC III471 eBioscience 
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CD4 PE RPA-T4 Biolegend APC SK-3 eBioscience 
CD45RA APC HI100 eBioscience 
CD56 PE MEM188 eBioscience 
CD8 APC SK-1 eBioscience 
CD80 PE 2D10.4 eBioscience 
CD83 PE HB15e eBioscience 
CD86 PE IT2.2 eBioscience 
CD95 Unlabelled SM1/23 Bender Medsystems 
CD95L FITC Alf2.1a Calbiochem 
CXCR4 PE 12G5 eBioscience 
DR4 Biotin DJR1 BD Pharmingen 
DR5 Biotin DJR2-4 BD Pharmingen 
FOXP3 APC 3G3 Miltenyi Biotech 
GATA-3 PE L50-823 BD pharmigen 
HLA-DR APC LN3 eBioscience 
IFN- FITC 4S.B3 eBioscience 
IL-23 subunit 19 Unlabelled BZ-23 Abcam 
IL-4 PE MP4-25D2 eBioscience 
Perforin PE B-D48 Abcam 
T-bet FITC 4B10 Biolegend 
TRAIL Biotin RIK-2 eBioscience Unlabelled
 
 
2.2 Protein immobilization on tissue culture plates 
Recombinant protein was diluted in phosphate buffered saline (PBS) to a 
concentration of 10 µg/ml, unless otherwise stated, and coated onto tissue 
culture plates. Volume of diluted protein added depends on the size of the 
tissue culture plates as stated in table 2. Plates were incubated at 37oC for 2 h 
or at 4oC overnight to allow for immobilization of proteins. After which, wells 
were washed 3 times with PBS and further experiments were performed with 
the immobilized protein.  
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Table 2. Volume of protein in tissue culture wells 
Type of tissue culture plate Volume of protein added/ µl 
96 well 100 
48 well 250 
24 well 500 
12 well 1000 
6 well 2000 
 
 
2.3 Cells and cell culture 
2.3.1 Cell lines 
The human monocytic cell line, THP-1, the human erythroleukemia cell line, 
K562, and the acute T cell leukaemia cell line, Jurkat, were obtained from 
ATCC. THP-1 and Jurkat cells were cultured in RPMI 1640 (Sigma-Aldrich) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS) (R10, refer 
to Appendix 1) while K562 cells were cultured in Iscoves modified 
dulbecco’s medium (IMDM) supplemented with 10% FBS (I10, refer to 
Appendix 1), respectively. Cells were maintained in a humidified incubator at 
37oC with 5% carbon dioxide and were passaged when 80% to 90% 
confluency was reached.  
 
2.3.2 Isolation of PBMCs, monocytes and T cells 
PBMCs were isolated from buffy coat of healthy donors obtained from the 
National University Hospital Blood Donation Centre. PBMCs were prepared 
by Ficoll-Hypaque density (1.077g/dl) (Sigma-Aldrich) gradient 
centrifugation. After which, PBMCs were washed with PBS containing 2mM 
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ethylenediamine tetraacetic acid (EDTA) (PBS + 2mM EDTA, refer to 
Appendix 2). Red blood cells (RBC) were removed by lysis using the RBC 
lysis buffer (refer to Appendix 2). PBMCs were used whole or PBMC subsets 
were isolated as described below, depending on the requirements of the 
experiments. During isolation of PBMC subsets, PBMCs were maintained in 
PBS containing 2mM EDTA and 0.5% bovine serum albumin (BSA) (MACS 
buffer, refer to Appendix 2)   
CD3+, CD4+ and CD8+ T cells were isolated from PBMCs using microbeads 
conjugated to anti-human CD3, CD4 and CD8 antibodies (Miltenyi Biotech), 
respectively. After antibody binding, PBMCs were passed through a column 
in a strong magnetic field. Cells labelled with microbeads were retained in the 
column and were flushed out after removal from the magnetic field. CD3+, 
CD4+ and CD8+ T cells were each more than 99% pure as determined by flow 
cytometric analysis after CD3, CD4 or CD8 staining.  
Monocytes and naïve CD4+ T cells were isolated from PBMCs via negative 
selection using the monocyte isolation kit II and naïve CD4+ T cell isolation 
kit II (Miltenyi Biotech), respectively. The monocyte isolation kit consists of a 
cocktail of biotin conjugated antibodies against CD3, CD7, CD16, CD19, 
CD56, CD123 and glycophorin A while the naïve CD4+ T cell isolation kit 
consist of biotin-conjugated antibodies against CD8, CD14, CD15, CD16, 
CD19, CD25, CD34, CD36, CD45RO, CD56, CD123, TCRHLA-DR and 
glycophorin A. These antibody cocktails recognise all cell types other than the 
cell of interest, monocytes or naïve CD4+ T cells. Cells which were 
recognised by the antibody cocktails were then labelled with anti-biotin 
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microbeads and will be retained when passed through a column in a strong 
magnetic field while monocytes or naïve CD4+ T cells were collected as flow-
through from the column. Monocytes and naïve CD4+ T cells were more than 
95% pure as determined by flow cytometric analysis after CD14 and CD45RA 
staining, respectively. 
All primary cells (PBMCs, monocytes and T cells) were cultured in R10 
containing 50 µg/ml streptomycin and 50 IU/ml penicillin (R10 + P/S, refer to 
Appendix 1). Cells were maintained in a humidified incubator at 37oC with 
5% carbon dioxide.  
 
2.3.3 In vitro generation of classical DCs and macrophages 
For the generation of DCs, isolated monocytes were cultured in the presence 
of 80 ng/ml GM-CSF and 100 ng/ml IL-4 for 7 days followed by maturation 
with 1 μg/ml LPS (Sigma-Aldrich) or 1 μg/ml LPS and 50 ng/ml IFN- for an 
additional day. Alternatively, DCs were matured by culturing in the presence 
of immobilized CD137-Fc.  
Isolated monocytes were cultured in the presence of 100 ng/ml M-CSF for a 
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2.4 Monocyte – T cell co-culture systems 
Various monocyte - T cell co-culture systems were established. In these 
culture systems, monocytes and T cells were derived either from the same 
donor (syngeneic) or from different donors (allogeneic).  
 
2.4.1 Syngeneic monocyte – T cell co-cultures 
In this culture system, both monocyte and T cells were derived from the same 
donor. After isolation, monocytes and T cells were mixed at a ratio of 1:1, 1:5 
or 1:10 to a total cell concentration of 1 X 106 /ml and cultured in pre-coated 
wells i.e. untreated, Fc or CD137-Fc coated wells in the presence of 
suboptimal concentration of the anti-CD3 antibody, clone OKT3. For time 
course experiments, monocytes were cultured on untreated, Fc or CD137-Fc 
coated wells for the desired length of time. At each time point, T cells were 
added to pre-treated monocytes at a ratio of 5:1 to a total cell concentration of 
1 X 106 /ml. These co-cultures were maintained for 18 h in R10 + P/S in the 
presence of suboptimal concentration of OKT3, an anti-CD3 antibody.  
 
2.4.2 Allogeneic MLR 
Allogeneic MLR were carried out to determine the ability of DCs to induce T 
cell proliferation and activation. Monocytes were pre-treated and harvested 
after 8 days post-isolation. During the pre-treatment, monocytes at a cell 
concentration of 1 X 106 /ml were cultured under Fc or CD137-Fc treatment 
for a total of 8 days. Also, monocytes were cultured under Fc or CD137-Fc 
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treatment for 7 days, followed by overnight culture in the presence of 1 µg/ml 
LPS or 1 µg/ml LPS and 50 ng/ml IFN-. For time course experiments, 
monocytes were pre-treated with Fc or CD137-Fc for the desired length of 
time. As controls, classical DCs were generated as described in section 2.3.3. 
After treatment, monocytes and DCs were harvested using PBS containing 10 
mM EDTA (refer to Appendix 3). Pre-treated monocytes and DCs were 
cultured with allogeneic CD3+, CD4+, CD8+ or naïve CD4+ T cells at a ratio 
of 1:10. Co-cultures were maintained in R10 + P/S for 4 to 7 days. T cell 
proliferation was quantified by thymidine incorporation or carboxyfluorescein 
diacetate succinimidyl ester (CFSE) dilution as described in section 2.5.  
 
2.5 Quantification of cell proliferation  
Two methods of measuring cell proliferation, thymidine incorporation and 
CFSE dilution, were employed. In thymidine incorporation, proliferating cells 
would incorporate radioactive hydrogen into its DNA. Therefore, the greater 
the cell proliferation, the greater the measured radioactivity of the cells. In 
CFSE dilution, cells were labelled with a fluorescent dye. Proliferating cells 
would lose some of their fluorescence to the daughter cells and hence, the 
greater the proliferation, the lesser the fluorescence of the cells. 
 
2.5.1 Thymidine incorporation 
Cells were pulsed with 0.5 μCi of 3H-thymidine (PerkinElmer) for the last 18 
h of the culture period and tissue culture plate containing these cells was 
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frozen after 3H-thymidine incorporation. Following this, the cultures were 
thawed and harvested onto a Packard Unifilter Plate using a MicroMate 196 
Cell Harvester and counted using a TopCount (Perkin Elmer). Each condition 
was assayed in triplicates.  
 
2.5.2 CFSE dilution 
In measuring cell proliferation by CFSE dilution, cells were first labelled with 
CFSE prior to start of the assay. CFSE staining is described in section 2.7.1. 
In assays where a mixture of cells were used, the identity of the proliferating 
cell type was determined by labelling the cells with fluorescent conjugated 
antibodies that recognize the surface markers, namely, CD3, CD20, CD56 and 
CD14. These markers represent T cells, B cells, NK cells and monocytes, 
respectively. Cell proliferation as indicated by a decrease in mean cell 
fluorescence is determined using flow cytometry.  
 
2.6 Determining suboptimal OKT3 concentration 
T cell proliferation is induced by addition of suboptimal concentration of 
OKT3, an anti-CD3 antibody. PBMCs were cultured in the presence of a 
range of OKT3 concentrations from 0 to 10 ng/ml.  Antibody was added and 
the culture was incubated for 3 days. Cell proliferation was determined by 
thymidine incorporation as described in section 2.5.1. 
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2.7 Flow cytometric analysis 
Flow cytometry is a tool that is used to analyse surface marker expression, 
cytokine production and transcription factor expression. It is also used to 
study apoptosis by looking at death receptor and ligand expression and the 
expression of proteins characteristic of apoptosis. Flow cytometry was 
performed on a CyAn FACS machine (Dako). For all flow cytometric assays 
using antibodies, non-specific staining was controlled by isotype matched 
antibodies. 
 
2.7.1 CFSE staining 
Labelling cells with CFSE (Invitrogen) serves as a tool for identification of 
cells of interest during flow cytometry and dilution of CFSE staining allows 
for quantification of cell proliferation by flow cytometry. CFSE is non-
fluorescent and can passively diffuse into cells. In the cells, the acetate groups 
are cleaved by intracellular esterases, yielding carboxyfluorescein 
succinimidyl ester which is highly fluorescent.  
Cells were labelled with CFSE according to manufacturer’s instructions. 
Briefly, cells of interest were resuspended into a single cell suspension at a 
concentration of 1 X 106 cells/ml in PBS containing 0.1% BSA. CFSE dye 
was added at a concentration of 1 µM or 8 µM, depending on the time course 
of the experiment, and the mixture was incubated for 10 min at 37oC. The 
staining was then quenched by adding 5 volumes of cold culture media. 
Following which, the cells were washed and used for further experiments.  
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2.7.2 Surface marker expression  
To determine surface marker expression, cells were stained with antibodies in 
PBS containing 0.5% BSA and 0.1% sodium azide (FACS buffer, refer to 
Appendix 3) for 1 h at 4°C in the dark. Cells were then washed and 
resuspended in 400 µl of FACS buffer. Antibodies used to study surface 
marker expression are listed in Table 1.  
 
2.7.3 Intracellular cytokine staining 
CD3+ cells, after stimulation with allogeneic DCs, were re-activated with 50 
ng/ml PMA and 100 nM A23187 in the presence of brefeldin A (eBioscience) 
for 5 h to 6 h. Brefeldin A stops transport of protein within the cells, thus 
preventing secretion of cytokines to the extracellular environment and allows 
for intracellular detection of cytokines. Cells were then harvested and stained 
for CD4 using APC conjugated anti-human CD4 antibodies. After which, 
cells were fixed and permeabilized using the BD Cytofix / Cytoperm fixation  
/ permeabilization kit (BD Biosciences) according to the manufacturer’s 
instructions. Briefly, fixation and permeabilization were carried out by 
incubating the cells in BD fixation / permeabilization solution for 20 min at 
4oC. Cells were then washed with 1X BD Perm wash buffer. After fixation 
and permeabilization, cells were stained with FITC-conjugated anti-IFN- 
antibody or PE-conjugated anti-IL-4 antibody in the presence of Fc receptor 
(FcR) blockers. Staining was done in 1X BD Perm wash buffer to ensure that 
cells remain permeabilized during staining.  
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2.7.4 Identification of transcription factors 
Expression of transcription factors T-bet, GATA-3 and FOXP3 were 
analysed. Quantification of T-bet and GATA-3 expression was performed 
with naïve CD4+ T cells while that of FOXP3 was done with total T cell 
population. T cells were first co-cultured with allogeneic pre-treated 
monocytes as described in section 2.4.2. For T-bet and GATA-3 expression, T 
cells were harvested and stained for CD4 expression. Cells were then fixed 
and permeabilized using the BD Cytofix / Cytoperm fixation / 
permeabilization kit (BD Biosciences) according to the manufacturer’s 
instructions. After fixation and permeabilization, cells were stained with 
FITC-conjugated anti T-bet or PE-conjugated anti-GATA-3 antibody in the 
presence of FcR blockers.  
To determine FOXP3 expression, T cells harvested from the MLR were 
stained for surface CD4 and CD25 expression. Following which, fixation and 
permeabilization of cells were performed using the FOXP3 staining buffer set 
(Miltenyi Biotec). After permeabilization, cells were stained for FOXP3 in the 
presence of FcR blockers. 
 
2.7.5 Death receptor and ligand expression 
In order to determine death receptor and ligand expression, cells were 
harvested, washed and were double stained for CD14 or CD3 and DR4, DR5, 
TNF-related apoptosis-inducing ligand (TRAIL) or CD95L in FACS buffer 
for 1 h at 4°C in the dark. After which, a secondary staining step with FITC-
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conjugated extravidin which will only bind to the biotin-conjugated antibodies 
was performed as antibodies against DR4, DR5 and TRAIL were biotin 
conjugated. In the secondary staining step, cells were incubated in FACS 
buffer for 30 minutes at 4°C in the dark. After which cells were washed twice 
and resuspended in 400 µl of FACS buffer for flow cytometric analysis.  
 
2.7.6 Apoptosis assay  
The apoptosis assay was carried out using the Annexin V apoptosis detection 
kit (BD Biosciences) according to the manufacturer’s instructions. Briefly, 
cells were washed and resuspended in 1X Annexin V buffer provided in the 
kit. For staining, 5 µl each of fluorescent conjugated Annexin V and 7-
aminoactinomycin D (7AAD) were added per 100 µl of cell suspension. Cells 
were incubated for 15 min at room temperature and the staining was quenched 
by addition of 400 µl of 1X Annexin V buffer. Three different fluorochrome-
conjugated Annexin V proteins, namely, FITC, APC and PE conjugated 
Annexin V were used depending on the requirements of the experiment. The 
percentage of apoptotic cells was determined by flow cytometric analysis. 
 
2.8 Identification of cell type undergoing apoptosis 
In apoptosis assays where a mixed cell population such as PBMCs or co-
cultures of monocyte and T cell at a ratio of 1:5 were used, cells were first 
labelled with fluorescent conjugated antibodies that recognize surface markers 
that are specific for each cell type before staining with the Annexin V 
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detection kit as described in section 2.7.6. The surface markers used to 
identify cell types include CD3, CD4, CD8, CD20, CD56 and CD14. These 
markers stain for CD3+ T cells, CD4+ T cells, CD8+ T cells, B cells, NK cells 
and monocytes, respectively. This allows for identification of specific cell 
types that are undergoing apoptosis.  
 
2.9 Functional Assays 
2.9.1 Phagocytosis  
FITC labelled latex beads, 1 µm in diameter, (Invitrogen) were used to 
quantify the phagocytic ability of pre-treated monocytes. Monocytes were 
cultured under no treatment, Fc or CD137-Fc treatment. At the desired time 
points, 50 beads per cell were added and the mixture was incubated at 37oC 
for 1 h. After which, phagocytosis was stopped by the addition of ice-cold 
PBS. Cells were washed, treated with trypsin-EDTA (refer to Appendix 3) to 
dislodge any surface adherent latex beads and then resuspended in 400 µl 
PBS. Flow cytometry was performed to determine the percentage of cells that 
had phagocytosed beads. 
 
2.9.2 Endocytosis  
Monocytes were cultured with no treatment or treated with Fc or CD137-Fc 
for the desired length of time. Pre-treated monocytes were incubated at 37oC 
for 30 min with FITC-labeled dextran (1 mg/ml, Sigma-Aldrich) at the desired 
time points. Endocytosis was stopped by adding ice-cold PBS containing 1% 
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FBS. Endocytosis was then analysed by flow cytometry to determine the 
mean fluorescence intensity (MFI) of the cells.  
 
2.9.3 Oxidative Burst 
Oxidative burst is a bactericidal mechanism in which ROS are formed to kill 
ingested pathogens. Dihydrorhodamine 123 (DHR123, Invitrogen) was used 
to determine the oxidative burst capacity of pre-treated monocytes. DHR123 
is an uncharged non-fluorescent agent that diffuses passively through the 
plasma membrane. In the presence of ROS, DHR123 is oxidised to the 
fluorescent rhodamine, thus indicating the oxidative burst capacity of the 
cells.  
In this assay, monocytes were first cultured under no treatment, Fc or CD137-
Fc treatment. At the desired time points, the pre-treated monocytes were 
activated with 20 µg/ml of PMA 10 min prior to the addition of 0.1 µg/ml 
DHR123. Cells were incubated for 30 min at 37oC. After which, cells were 
harvested and washed to remove excess DHR123. The MFI of cells was 
determined by flow cytometry. 
 
2.10 Potential cytolytic activity of T cells 
2.10.1 Perforin expression 
Following an allogeneic MLR, as described in section 2.4.2, cells were 
harvested and cell number determined. Cells were plated out at a 
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concentration of 0.5 X 106 cells/ml and restimulated with 50 ng/ml PMA and 
1 µM A23187. After 1 h incubation, brefeldin A (eBioscience) was added and 
the culture was incubated for an additional 4 h to 5 h. Following which, cells 
were harvested and stained with an APC-conjugated anti-human CD8 
antibody to stain for CD8+ cells. Cells were then fixed and permeabilized 
using the BD Cytofix / Cytoperm fixation / permeabilization kit (BD 
Biosciences) according to manufacturer’s instruction as described in section 
2.7.3. After fixation and permeabilization, cells were stained for perforin 
using a PE-conjugated anti-perforin antibody.  
 
2.10.2 Flow cytometry based killing assay  
In this CTL assay, K562 cells were used as target cells while CD8+ T cells 
after stimulation in an allogeneic MLR were used as effector cells. The CTL 
activity of CD8+ T cells was determined by their ability to kill the target cells. 
K562 cells were first labelled with CFSE as described in section 2.7.1. This 
allows for identification of the target cells during flow cytometric analysis. 
CD8+ T cells that had been activated by an allogeneic MLR, as described in 
section 2.4.2 were then co-cultured with the CFSE-labelled K562 cells at 
effector: target ratios of 1:1, 10:1 and 20:1. After overnight co-culture, total 
cells were harvested and an apoptosis assay using the Annexin V apoptosis 
detection kit (BD Biosciences) was performed as described in section 2.7.6. 
Flow cytometric analysis was then performed to determine the percentage of 
apoptotic cells in the CFSE positive population.  
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2.11 Determination of the importance of soluble factors 
Experiments were performed to determine if soluble factors alone were 
sufficient to induce the observed effects or whether cell to cell contact was 
important. Transwell assays and transfer of soluble factors from one culture 
condition to another were performed to determine the importance of cell to 
cell contact.  
 
2.11.1 Transwell assays 
Monocytes were cultured on untreated, Fc or CD137-Fc coated tissue culture 
plates at a concentration of 1 X 106 cells/ml. A transwell with a pore size 0.4 
µm (Greiner) was placed in each of the wells and an equal concentration of T 
cells was added to each of the transwell. After 24 h co-incubation, T cells 
were harvested and the percentage of apoptotic cells was measured. 
 
2.11.2 Transfer of soluble factors  
PBMCs, monocytes and co-cultures of monocyte and T cells at a ratio of 1:1 
were cultured as described in section 2.4.1. After overnight incubation, 
supernatants of the cultures were harvested and transferred to T cells. These T 
cells were either untreated or activated with 0.5 µg/ml of OKT3. T cell 
apoptosis was then determined in an apoptosis assay. 
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2.12 Neutralization Assays 
2.12.1 Neutralization of death inducing factors 
Culture of PBMCs and co-cultures of monocyte and T cells at a ratio of 1:5 
were performed as described in section 2.4.1. For TRAIL and CD95 
neutralization studies, cells were stimulated in the presence of neutralizing 
antibodies; anti-TRAIL and anti-CD95, respectively. As negative controls, 
cells were stimulated in the presence of an isotype control.  
Positive controls were set up for both TRAIL and CD95 neutralization 
studies. In these positive controls, Jurkat cells were cultured in the presence of 
100 ng/ml recombinant human TRAIL (rhTRAIL) or 100 ng/ml agonistic 
anti-CD95 antibodies overnight. The ability of neutralizing anti-TRAIL and 
anti-CD95 antibodies to block TRAIL or CD95 induced apoptosis was then 
determined in an apoptosis assay.  
 
2.12.2 Neutralization of H2O2 by catalase 
PBMCs and co-cultures of monocyte and T cells at a ratio of 1:5 were 
cultured as described in section 2.4.1 in the presence of 10,000 U/ml of 
catalase. The percentage of apoptotic cells was then determined by an 
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2.12.3 Cytokine neutralization 
Monocytes were co-cultured with allogeneic T cells as described in section 
2.4.2. During the MLR reaction, anti-IL-23p19 antibodies were added to 
neutralize secreted IL-23. As controls, MLRs were performed without 
antibodies or in the presence of an isotype control. After 5 days of co-culture, 
supernatants were harvested and concentrations of IL-17 in the supernatants 
were determined by an enzyme linked immunosorbent assay (ELISA).  
 
2.13 ELISA  
The concentrations of IL-8 and IL-12p70 in cell supernatants were determined 
using the human IL-8 and IL-12p70 DuoSet ELISA kits (R&D Systems), 
respectively. The concentrations of TGF-, IL-10, IL-4, IFN-, IL-13, IL-23 
and IL-17 in cell supernatants were determined by Ready-Set-Go! Human 
TGF-, IL-10, IL-4, IFN- IL-13, IL-23 and IL-17 ELISA kits (eBioscience), 
respectively. ELISAs were performed according to the manufacturers’ 
instructions. Each sample was assayed in triplicate within each experiment.  
 
2.14 Morphological Changes 
Monocytes were cultured in the presence of Fc, CD137-Fc or GM-CSF and 
IL-4. At day 7 of culture, LPS and IFN- were added to GM-CSF and IL-4 
cultures for an additional 18 h to induce maturation of classical DCs. 
Morphological changes of these cells were documented on day 8 of culture 
Materials & Methods 
56 
 
using the Zeiss Axiovert 40 inverted microscope (Zeiss) and Canon 
Powershot G6 digital camera.  
 
2.15 Statistics 



















This chapter addresses the effects of CD137L signalling in monocytes and the 
consequence of interactions between CD137 treated monocytes and T cells. 
The first part characterizes the inhibitory effects of CD137L signalling in the 
different PBMC subsets and shows monocyte dependent induction of T cell 
apoptosis by treatment with CD137 protein. This is followed by an evaluation 
of the effects of CD137L signalling on monocyte functions and 
differentiation. Finally, effects of CD137 treated monocyte on T cell 
differentiation and functions are presented. Throughout this section, the terms 
CD137 treatment or CD137L activation is used to describe CD137L 
signalling, which refers to signalling through CD137L upon receptor / ligand 
interaction and these terms are used interchangeably.      
 
3.1 CD137L mediated inhibition of PBMC subsets 
3.1.1 CD137L activation inhibits PBMC proliferation 
CD137L agonists have been shown to inhibit proliferation and to induce 
apoptosis of anti-CD3 stimulated PBMCs (Schwarz et al, 1996; Michel et al, 
1999; Ju et al, 2003). In order to confirm these observations, it was of interest 
to determine the suboptimal anti-CD3 antibody, clone OKT3, concentration 
for stimulation of PBMCs. PBMCs were cultured with a range of OKT3 
concentration from 0 ng/ml to 5 ng/ml for 3 days and proliferation of these 
cells was determined on day 4. PBMC proliferation increased with increasing 
concentrations of OKT3 up to 1 ng/ml. Highest PBMC proliferation of 16,632 
± 2104 counts per minute (cpm) was achieved at an OKT3 concentration of 1 




2532 cpm at an OKT3 concentration of 5 ng/ml (Fig. 3A). A decrease in 
proliferation at higher antibody concentrations suggested that the antibody 
concentration was too high and had induced AICD. The suboptimal OKT3 
concentration of 0.5 ng/ml was chosen for subsequent studies involving 
PBMC proliferation and T cell apoptosis.  
In this study, stimulation of CD137L was achieved by immobilizing CD137-
Fc protein on tissue culture plates to allow for cross-linking of CD137L. 
Recombinant human CD137, CD137-Fc, consists of the extracellular domain 
of human CD137 fused to the constant domain of human IgG1 (Fc). Fc 
protein coated plates or uncoated plates (PBS) served as negative controls to 
ensure that effects observed under CD137-Fc treatment was due to interaction 
between CD137 and its ligand. Consistent with published data, culturing of 
anti-CD3 stimulated PBMCs with CD137, resulted in a significant decrease in 
proliferation as compared to untreated (PBS) or Fc treated cultures (Fig. 3B).  
3H-thymidine incorporation proliferation data showed that there was a general 
decrease in proliferation of PBMCs. It does not however, identify which cell 
population within the PBMCs were affected by CD137 treatment. 
Quantification of cell proliferation by CFSE dilution after identification of the 
various cell populations including T cells, monocytes, B cells and NK cells 
using antibodies against CD3, CD14, CD20 and CD56, respectively, showed 
that CD137 treatment inhibited proliferation of all cell populations. Inhibition 
of proliferation in the CD14+ population was minimal as CFSE MFI was only 
slightly higher under CD137 treatment at 1926.9 as compared to Fc or no 




proliferation was observed in the T cell, B cell and NK cell population after 
CD137 treatment (Fig. 3C). 
 
3.1.2 CD137L activation selectively induce T cell apoptosis 
Inhibition of PBMC proliferation upon CD137 treatment was accompanied by 
increased cell death. The ability to detect cell death by Annexin V staining 
confirmed earlier findings that CD137 treatment induces apoptosis in PBMCs. 
The percentage of late apoptotic cells represented by Annexin V+ and 7AAD+ 
population increased from 7.1% in PBMCs treated with Fc to 22.2% in those 
cultured in the presence of CD137 (Fig. 4A). No difference in percentage of 


















































Figure 3. CD137 mediated inhibition of PBMC proliferation. (A) PBMCs 
were cultured over a range of OKT3 concentration (0 to 5 ng/ml) for a period 
of 3 days. At day 4, proliferation was quantified by 3H-thymidine 
incorporation. Proliferation was measured as cpm. (B) PBMC activated with 
0.5 ng/ml OKT 3 was cultured under no treatment, Fc or CD137-Fc treatment. 
At day 4, proliferation was determined by 3H-thymidine incorporation. (C) 
PBMCs were CFSE labelled, activated with 0.5 ng/ml OKT 3 and cultured 
under no treatment, Fc or CD137-Fc treatment for 3 days. Proliferation of 
CFSE labelled PBMC subsets was determined by flow cytometry after 
staining for the surface markers CD3, CD14, CD20 and CD56. Numbers in 








Induction of apoptosis in the PBMC subsets after no treatment (PBS), Fc or 
CD137 treatment was determined by staining cells with 7AAD and with 
antibodies against CD3, CD14, CD20 or CD56, surface markers for T cells, 
monocytes, B cells and NK cells, respectively. CD137 treatment did not 
increase cell death in the monocyte, B cell and NK cell populations. However, 
cell viability was reduced in the T cell population after CD137 treatment. The 
percentage of CD3+, 7AAD- cells decreased from 63.1% in Fc treated PBMCs 
to 55% in those treated with CD137. This decrease in CD3+ cell viability after 
CD137 treatment was accompanied by a 4 fold increase in the percentage of 
7AAD+ cells (Fig. 4B). Hence, CD137L stimulation not only inhibits PBMC 
proliferation but also selectively induces apoptosis in T cells. 
 
3.1.3 CD137 mediated T cell apoptosis is dependent on monocytes 
PBMC is a heterogeneous population of cells and the different PBMC subsets 
can interact with one another to influence the outcome of an immune 
response. As in the case of T cell apoptosis mediated by CD137 treatment, 
other PBMC subsets are involved in the induction of T cell apoptosis.  
Treatment of PBMCs with CD137 resulted in a doubling of the percentage of 
apoptotic cells as compared to Fc treated cells (15.9% versus 30.8%). 
However, CD137 treatment of a pure T cell population only resulted in a 
slight increase from 20.7% to 26.5% in the percentage of apoptotic cells as 
compared to Fc treated cells (Fig. 5A). This trend implied that other PBMC 



















Figure 4. CD137L activation selectively induces T cell apoptosis. PBMCs 
were cultured under no treatment (PBS), Fc or CD137-Fc treatment in the 
presence of 0.5 ng/ml of OKT3. (A) After a 24 h culture period, cells were 
stained with Annexin V and 7AAD and analysed by flow cytometry. (B) After 
a 24 h culture period, cells were stained with 7AAD and antibodies against 
CD3, CD14, CD20 or CD56 and analysed by flow cytometry. (A,B) Numbers 








when pure monocytes and T cells were co-cultured at a ratio of 1:1, apoptosis 
induced by CD137 was tripled as compared to Fc treatment (18.4% versus 
51.3%) (Fig. 5A). Monocyte dependency of CD137-induced T cell apoptosis 
was further confirmed by co-culturing pure monocyte and T cell populations 
at ratios of 1:10, 1:5 and 1:1. As the monocyte concentration in the co-cultures 
increased from a ratio of 1:10 to 1:1, the percentage of apoptotic cells 
increased from 34.3 ± 1.3% to 63.6 ± 1.5%. Hence, the greater the amount of 
monocytes in the co-culture, the greater the percentage of apoptotic cells, 
suggesting that monocytes play a role in mediating CD137 induced T cell 
apoptosis (Fig. 5B).  
In order to determine whether monocyte dependent, CD137 induced T cell 
apoptosis affect the different T cell populations, i.e. CD4+ and CD8+ T cell 
populations, equally, purified CD4+ or CD8+ T cells were co-cultured with 
monocytes at a ratio of 1:1 under Fc or CD137 treatment. In both T cell 
populations there was a comparable increase in percentage of 7AAD+ cells 
after CD137 treatment. In the CD4+ and CD8+ populations, the percentage of 
7AAD+ cells increased from 3.4% to 4.8% and 4.2% to 6.3%, respectively, 
after CD137 treatment as compared to Fc treatment (Fig. 6). Hence, both 



















Figure 5. CD137 induced T cell apoptosis is dependent on monocytes. (A) 
PBMCs, T cells or a co-culture of monocytes and T cells at a ratio of 1:1 
(T+M) were cultured under no treatment (PBS), Fc or CD137-Fc treatment in 
the presence of 0.5 ng/ml of OKT3. (B) PBMC or co-cultures of T cells and 
monocytes at ratios of 10:1, 5:1 and 1:1 were cultured under no treatment, Fc 
or CD137-Fc treatment in the presence of 0.5 ng/ml OKT3. (A, B) After 24 h, 
cells were harvested and stained with Annexin V and 7AAD. Percentage of 
apoptotic cells was determined by flow cytometry. Numbers on the y-axis 






























































Figure 6. CD137 induced monocyte dependent apoptosis affects CD4+ and 
CD8+ T cells equally. Pure CD4 or CD8 T cell population was co-cultured 
with monocytes at a ratio of 1:1 under Fc or CD137-Fc treatment in the 
presence of 0.5 ng/ml OKT3. After 24 h co-culture, cells were harvested and 
stained with Annexin V and 7AAD. The percentage of apoptotic cells was 
determined by flow cytometry. Numbers in histograms indicate percentage of 


















3.1.4 CD137 induced, monocyte dependent T cell apoptosis requires cell 
to cell contact 
It has been determined that monocytes are important in mediating the effects 
of CD137L signalling on T cells. Further analysis is required to determine the 
mechanism by which CD137 induces T cell apoptosis. It was possible that 
monocytes upon activation by CD137 produce soluble factors that mediate T 
cell apoptosis. In order to confirm this hypothesis, monocytes were cultured 
under no treatment (PBS), Fc or CD137 treatment and T cells were separated 
from monocytes by a transwell. This allows for free transfer of soluble factors 
between the upper and lower chambers while preventing cell to cell contact.  
By preventing contact between T cells and monocytes, CD137 treatment no 
longer resulted in an increase in apoptosis as compared to untreated or Fc 
treated cells. This is in contrast to the significant increase in apoptosis under 
CD137 treatment when monocytes and T cells were allowed to interact where 
49.7% of cells stained positive for Annexin V and 7AAD as compared to Fc 
treatment which only had 18.2% of late apoptotic cells (Fig. 7A). This 
suggested that soluble factors, produced upon CD137 treatment, were 
insufficient in mediating T cell apoptosis. This observation was further 
confirmed when conditioned supernatants from PBMCs, monocytes or co-
culture of monocytes and T cells at a ratio of 1:1 after CD137 treatment could 
not induce apoptosis in both resting and anti-CD3 activated T cells. No 
difference in the percentage of apoptotic cells was observed in resting and 
activated T cells treated with CD137 conditioned medium and Fc or untreated 

























Figure 7. CD137 induced T cell apoptosis requires contact between 
monocytes and T cells. (A) Monocytes and T cells at a ratio of 1:1 were 
either co-cultured or separated by a transwell and cultured under no treatment 
(PBS), Fc or CD137-Fc treatment in the presence of 0.5 ng/ml of OKT3. 
(B,C) PBMCs, monocytes and co-cultures of T cells and monocytes at a ratio 
of 1:1 were cultured under no treatment, Fc or CD137-Fc treatment in the 
presence of 0.5 ng/ml OKT3 concentration. After 24 h culture, supernatants 
were harvested and added to (B) unactivated T cells and (C) activated T cells. 
(A, B, C) After 24 h culture, T cells were harvested and the percentage of 
apoptotic cells was determined by flow cytometry. (A) Numbers in histograms 
indicate percentages of cells in each quadrant. (B, C) Numbers on y-axis 

































showed that T cell apoptosis induced by CD137L signalling requires 
monocyte and T cell contact.  
 
3.1.5 CD137 induced T cell apoptosis is independent of CD95 and TRAIL 
The requirement for cell-to-cell contact between monocytes and T cells in 
mediating CD137 induced T cell apoptosis suggested a role for membrane 
bound proteins in mediating apoptosis. Two of the most well characterized 
membrane bound death inducing proteins are the CD95 receptor / ligand and 
the TRAIL / death receptor systems. The CD95 receptor / ligand system has 
been identified to belong to the TNFR / TNF superfamily that mediate 
apoptotic signals and have been implicated in TCR-triggered apoptosis. CD95 
mediated apoptosis plays a role in various physiological and 
pathophysiological events including immune homeostasis, tissue turnover and 
cell mediated cytotoxicity (Corazza et al, 2004). In T cells, the CD95 receptor 
ligand system has been shown to be important in negative selection of 
thymocytes and hence plays a crucial role in maintaining peripheral T cell 
tolerance (Walczak and Krammer, 2000).  
TRAIL, another apoptosis inducing protein is also part of the TNF 
superfamily (Wiley et al, 1995). Several receptors that can recognise TRAIL 
have been identified. These include death receptor (DR) 4, DR5, decoy 
receptor (DcR) 1, DcR2 and the soluble receptor osteoprotegerin (OPG). Of 
these receptors, only engagement of TRAIL with DR4 and DR5 would 
transmit apoptotic signals into cells bearing the receptors (Degli-Esposti, 




in tumour cell lines while sparing normal cells (Walczak and Krammer, 
2000). More recently, TRAIL has also been implicated in immune regulation. 
In T cells, similar to CD95, TRAIL may have a role to play in negative 
selection of thymocytes and may therefore be important in maintaining T cell 
tolerance (Corazza et al, 2004).  
An analysis of the expression of these death inducing proteins upon CD137 
treatment suggested that they may have a role to play in mediating monocyte 
dependent CD137 induced T cell apoptosis. Within the T cell population of 
PBMCs, CD137 treatment resulted in an increase in the expression of both 
DR4 and DR5 as compared to Fc treatment (0.6% to 4%) (Fig. 8). CD137 
resulted in an even greater increase in expression of both DR4 and DR5 on T 
cells when T cells were cultured with a higher concentration of monocytes at a 
ratio of 5:1. Expression of DR4 increased from 1.8% under Fc treatment to 
38.8% upon CD137 treatment. Similarly, expression of DR5 increased from 
2.1% to 36.9% (Fig. 8). Hence, as in the case of cell death, expression of 
death receptors on T cells was correlated to the amount of monocytes in the 
co-culture. No changes in expression of DR4 and DR5 were observed in the 
monocyte population under all conditions. Decrease in percentage of CD14+ 
cells after CD137 treatment can be attributed to loss of cells due to its 
adherence and the down-regulation of CD14 expression upon CD137L 
activation and this will be addressed in section 3.2.2.  
Apart from expression of the death receptors, the expression of CD95L and 
TRAIL, the ligands for CD95 and DR4 and DR5, respectively, were also 
examined. Similar to expression of the death receptors, expression of CD95L 






Figure 8. CD137 treatment increases expression of death receptors on T 
cells. PBMCs or T cell - monocyte co-cultures at a ratio of 5:1 were cultured 
under Fc or CD137-Fc treatment in the presence of 0.5 ng/ml of OKT3. After 
24 h, cells were harvested and stained for CD14 or CD3 and DR4 or DR5. 
Percentage of cells expressing these markers was determined by flow 











Figure 9. CD137 treatment increases expression of CD95L and TRAIL on 
T cells. PBMCs or T cell - monocyte co-cultures at a ratio of 5:1 were 
cultured under Fc or CD137-Fc treatment in the presence of 0.5 ng/ml of 
OKT3. After 24 h, cells were harvested and stained for CD14 or CD3 and 
CD95L or TRAIL. Percentage of cells expressing these markers was 
determined by flow cytometry. Numbers in histograms indicate the 









the death ligands was also limited to the T cell population and correlated with 
monocyte numbers (Fig. 9).  
This increase in expression of CD95L, TRAIL and the death receptors, DR4 
and DR5, in T cells upon CD137 treatment implied that CD137 may mediate 
T cell apoptosis through the CD95 receptor / ligand or death receptor / TRAIL 
system. However, neutralization studies proved otherwise. Addition of 
neutralizing anti-TRAIL and anti-CD95 antibodies did not rescue T cell 
apoptosis induced upon CD137 treatment. Consistent with data presented 
earlier, CD137 resulted in an increase in the percentage of apoptotic cells 
from 5.9% to 11.3% in the PBMC population and an increase from 9.3% to 
50.1% in the co-culture of T cells and monocytes at a ratio of 5:1. Upon 
addition of neutralizing anti-CD95 or anti-TRAIL antibodies, the percentage 
of apoptotic cells remained high at about 12% in the PBMC population and 
50% in the T cell - monocyte co-culture (Fig. 10A).  
The functionality of these neutralizing antibodies was proven by their ability 
to rescue CD95 or TRAIL mediated cell death in Jurkat cells. In Jurkat cells, 
addition of agonistic anti-CD95 antibodies or rhTRAIL protein increased cell 
death by about 2 fold (Fig. 10B). However, addition of neutralizing anti-CD95 
or anti-TRAIL antibodies to Jurkat cells treated with agonistic anti-CD95 
antibodies or rhTRAIL reduced cell death to levels prior to treatment (Fig 
10B). With the functionality of the neutralizing antibodies confirmed, the 
inability of these antibodies to rescue CD137 mediated T cell apoptosis 
strongly suggest that the CD95 receptor / ligand and TRAIL / death receptor 




















































Figure 10. CD137 mediated T cell apoptosis is independent of the CD95 
receptor / ligand and TRAIL / death receptor systems. (A) PBMCs or T 
cell monocyte co-cultures at a ratio of 5:1 were cultured under no treatment 
(PBS), Fc or CD137-Fc treatment in the presence of 0.5 ng/ml of OKT3. 
Additionally, neutralizing anti-CD95, anti-TRAIL antibodies or isotype 
control antibodies were added to CD137 treated cells throughout the entire 
culture period. (B) Jurkat cells were treated with agonistic anti-CD95 
antibodies or rhTRAIL to induce cell death. Neutralizing anti-CD95, anti-
TRAIL or isotype control antibodies were added to inhibit induction of 
apoptosis. (A,B) After 24 h culture, cells were harvested and apoptosis was 
determined by flow cytometry after AnnexinV / 7AAD staining. Numbers in 








3.1.6 CD137 mediated T cell apoptosis is dependent on ROS 
Apart from the membrane bound death inducing proteins described above, 
ROS, which includes superoxide, H2O2, and hydroxyl radicals, have been 
shown to play a role in mediating apoptosis. Several death inducing signals 
such as TNF, dexamethasone and chemotherapeutic drugs are associated with 
elevated ROS levels in cells (Buttke and Sandstrom, 1994). In T cells, ROS 
has been implicated in sensitizing these cells to apoptosis. Apoptosis can be 
influenced by both extracellular and intracellular produced ROS. It has been 
suggested that elevated ROS levels activate signalling pathways which 
eventually lead to suppression of Bcl-2 expression leading to increased 
susceptibility of T cells to apoptosis (Tripathi and Hildeman, 2004). Not 
surprisingly, intracellular ROS has been implicated in monocyte mediated T 
cell apoptosis (Wesch et al, 1998).  Hence, the role of ROS in mediating 
CD137 induced T cell apoptosis was investigated. As expected, treatment of 
PBMCs or T cell-monocyte co-cultures with CD137 resulted in an increase in 
apoptosis. Interestingly, addition of catalase, a H2O2 scavenger, completely 
rescued cell death induced by CD137 and percentage of apoptotic cells under 
CD137 treatment was reduced to levels comparable to that of cells under no 
treatment or Fc treatment (Fig. 11). This strongly suggested a role for ROS in 
mediating CD137 induced T cell apoptosis.  
Further analysis also showed that prevention of H2O2 generation from 
superoxide inhibited CD137 induced T cell apoptosis. ROS responsible in 
inducing T cell apoptosis was shown to be produced internally in T cells and 
increase in ROS upon CD137 treatment was closely correlated to monocyte 






Figure 11. Inhibition of ROS completely blocks CD137 induced T cell 
apoptosis. PBMCs or T cell-monocyte co-cultures at a ratio of 5:1 were 
cultured under no treatment (PBS), Fc or CD137-Fc treatment in the presence 
of 0.5 ng/ml of OKT3. Additionally, catalase at a concentration of 104 
units/ml was added to all culture conditions throughout the entire culture 
period. After 24 h, cells were harvested, and the percentage of apoptotic cells 
was determined by flow cytometry after Annexin V/ 7AAD staining. Numbers 









implied that monocytes activated by CD137 could induce production of H2O2 
in T cells which in turn mediate T cell apoptosis. More in depth evaluation of 
the effects of CD137 treatment on monocyte functions may provide an idea of 
how CD137 influences monocyte-T cell interactions which eventually leads to 
T cell apoptosis.  
 
3.2 Characterization of CD137L activated monocytes 
3.2.1 CD137L signalling activates monocytes 
CD137L activation has been described to promote pro-inflammatory cytokine 
production while inhibiting anti-inflammatory cytokine production. CD137 
treatment also induces morphological changes in monocytes (Langstein et al, 
1998; Langstein and Schwarz, 1999; Langstein et al, 2000). These 
observations suggest an activating role of CD137 on monocytes.  
Before verifying the effects of CD137L signalling in monocytes, it was of 
interest to determine the expression profile of CD137L in monocytes isolated 
from buffy coats of healthy donors. Consistent with published data, resting 
monocytes do express CD137L. Monocyte isolated from different donors 
express varying amounts of CD137L but the percentage of CD137L 
expression generally ranges between 45% and 60% (Fig 12A).   
In order to verify activation of monocytes by CD137L signalling, monocytes 
were cultured on plates that were coated with 10 µg/ml of the fusion protein, 
CD137-Fc. As controls, cells were cultured in plates coated with an equal 




Indeed, CD137 treatment resulted in monocyte activation as indicated by an 
increased production of IL-8. CD137 treatment significantly increased IL-8 
production as compared to untreated or Fc treated cells (Fig. 12B). The ability 
of anti-CD137L antibodies, clone 5F4 and C65-485, to increase IL-8 
production in monocytes as compared to isotype control antibodies (Fig. 12B) 
further verified that activation of monocytes upon CD137 treatment was due 
to specific interaction between coated CD137-Fc protein and CD137L 
expressed on monocytes.   
 
3.2.2 CD137L signalling inhibits macrophage activities 
Earlier work in the lab has shown that CD137L stimulation promotes 
proliferation and myeloid colony formation which is followed by monocyte 
and macrophage differentiation of CD34+ hematopoietic stem cells (Jiang et 
al, 2008(b)). Since CD137 treatment activates monocytes, it would be 
expected that CD137L signalling would similarly induce macrophage 
differentiation. However, analysis of both phagocytic activity and oxidative 
burst capacity of CD137 treated monocytes suggests otherwise.  
CD137 treatment resulted in a significant decrease in the percentage of cells 
that phagocytosed latex beads as compared to Fc or untreated cells. As early 
as 1 day after incubation of monocytes with CD137-Fc, the percentage of 
phagocytosing cells decreased to 22% as compared to Fc treated cells which 
showed 64% phagocytosing cells. Throughout the seven days of culture, the 


















Figure 12. CD137L signalling activates monocytes. (A) Monocytes isolated 
from buffy coats of healthy blood donors were stained for CD137L using the 
anti-CD137L antibody, clone 41B-436. Percentage of CD137L expressing 
cells was determined by flow cytometry. Black and grey histograms represent 
isotype control and anti-CD137L stained cells, respectively. Numbers in 
histogram represent percentage of positive cells and MFI. (B) Monocytes 
were cultured under no treatment (PBS), Fc or CD137-Fc treatment. 
Additionally, monocytes were cultured in the presence of anti-CD137L 
antibodies (clone 5F4 or C65-485) or isotype control antibodies. After 16 h of 
culture, supernatants were harvested and IL-8 levels were determined by 
ELISA. Depicted are means ± standard deviations of triplicate measurements. 






















that of untreated or Fc treated cells. No differences in the phagocytic activity 
of untreated and Fc treated cells were observed (Fig. 13A).  
Similarly, when monocytes were activated to induce oxidative burst, CD137 
treatment for as early as 1day, could inhibit production of ROS, as depicted by 
a decrease in MFI. At 1 day after CD137 treatment, MFI decreased from 180 
in Fc treated cells to 36. The oxidative burst capacity of CD137 treated 
monocytes remained low throughout 4 days of culture and no difference was 
observed between the oxidative burst capacity of untreated and Fc treated 
cells (Fig. 13B).  
Inhibition of both phagocytic activity and oxidative burst capacity of CD137 
treated monocytes suggested an inhibition of macrophage activities. In order 
to confirm that indeed macrophage activities of CD137 treated monocytes 
were reduced, the phagocytic activity of CD137 treated monocytes was 
compared to that of classical macrophages. These macrophages were 
generated by culturing monocytes in the presence of M-CSF for 7 days. As 
expected, classical macrophages showed a high phagocytic potential that was 
comparable to that of untreated or Fc treated monocytes. Interestingly, when 
monocytes were cultured in the presence of GM-CSF and IL-4 for 7 days to 
generate classical imDCs, phagocytic activity of these DCs was comparable to 
that of CD137 treated monocytes (Fig. 13A). This implied that perhaps 
CD137 could promote differentiation of monocytes to DCs.  
To confirm the possibility that CD137 promotes monocyte to DC 
differentiation, CD14 expression and endocytic capacity of CD137 treated 


























































Figure 13. CD137L signalling suppresses macrophage functions. 
Monocytes were cultured under no treatment (PBS), Fc or CD137-Fc 
treatment for 1, 2, 3, 4 or 7 days. Additionally, monocytes were differentiated 
to DCs or macrophages by culturing them in the presence of 80 ng/ml GM-
CSF and 100 ng/ml IL-4 or 100 ng/ml M-CSF, respectively. (A) At each 
timepoint, phagocytosis was determined by the ability of the cells to take up 
FITC-labelled latex beads (1 µm). As controls, autofluorescence of cells was 
determined. Depicted are the flow cytometry histograms on the top and a 
graphical representation of the percentage of fluorescent cells at the bottom. 
(B) Oxidative burst was determined by first pre-activating cells using 20 
µg/ml PMA, followed by addition of DHR123. As controls, autofluorescence 
of cells was determined. Depicted are flow cytometry histograms on the left 
and the graphical representation of the MFI on the right. **p<0.01 using a 






















is known that DCs express low or no CD14. CD137 treatment resulted in a 
decrease in CD14 expression as early as day 1 of culture. During the 7 days of 
culture, CD14 expression remained high at about 90% in untreated or Fc 
treated cells. However, for cells treated with CD137, CD14 expression was 
reduced to about 60% from day 1 to day 4 and by the 7th day of culture, CD14 
expression was reduced to 44.9% with an MFI of 81.1 (Fig. 14A). 
While phagocytosis and oxidative burst can be used as measures of 
macrophage activity, endocytosis can be used as a measure of DC activity. 
Endocytosis was determined by the ability of monocytes to uptake fluorescent 
labelled dextran. Unlike the decrease in phagocytic potential, the endocytic 
activity of monocytes was increased upon CD137 treatment. Exposure of 
monocytes to CD137 enhanced the rate of endocytosis throughout the 9-day 
culture period. The endocytic activity of monocytes was increased as early as 
1 day after CD137 treatment. The MFI of monocytes was increased from 49 ± 
0.7 in Fc treated cells to 68.8 ± 1.4 in CD137 treated cells after 1 day of 
culture. Highest endocytic activity of CD137 treated monocytes with an MFI 
of 120.2 ± 14.8 was achieved after 7 days of culture. At day 9, endocytic 
activity of CD137 treated monocytes with an MFI of 106.4 ± 9.4 was 
comparable to the endocytic activity at day 7. Endocytic activity of CD137 
treated monocytes was also compared to that of classical DCs. As expected, 
imDCs showed high endocytosis (200.7 ± 5.7) and its endocytic activity was 
reduced upon maturation (85.8 ± 2.3) (Fig. 14B). The functional profile of 
CD137 treated monocytes strongly mimics that of classical DCs but imDCs 

















































Figure 14. CD137L signalling induces DC-like characteristics. Monocytes 
were cultured under no treatment (PBS), Fc or CD137-Fc treatment for 1, 2, 3, 
7 or 9 days and analysed by flow cytometry. Additionally, monocytes were 
differentiated to DCs by culturing them in the presence of 80 ng/ml GM-CSF 
and 100 ng/ml IL-4. Maturation of DCs was achieved by culturing imDCs in 
the presence of 1 µg/ml LPS and 50 ng/ml IFN- for a further 2 days. (A) At 
each of the timepoints, cells were stained for CD14. Numbers in histograms 
indicate percentages of positive cells and MFI. Black and grey histograms 
represent isotype control and CD14 expression, respectively. (B) Endocytic 
capacity of the cells was determined by their ability to take up FITC-labelled 
dextran. As controls, autofluorescence of cells was determined. Depicted is 
the graphical representation of the MFI. *p<0.05; **p<0.01 using a two-tailed 






























3.2.3 CD137L activation promotes monocyte to DC differentiation 
Generally, CD137 treated monocytes have been shown to be similar to 
classical DCs in terms of phagocytosis, endocytosis and oxidative burst 
potential. Morphologically, CD137L signalling induces features similar to that 
of classical DCs that had been matured in the presence of 1 µg/ml LPS and 50 
ng/ml IFN-Both CD137 treated monocytes and classical mature DCs 
(mDCs) show round, “fried-egg” like and elongated, spindle-like 
morphologies and these cells were adherent on the surface of tissue culture 
plates. However, CD137 treated monocytes were more strongly adhered to 
tissue culture plates than classical mDCs. Unlike CD137 treated monocytes, 
Fc treated cells remained round and detached from the tissue culture plates 
which implied that these cells remained unactivated, even after 8 days of 
culture. Classical imDCs too remained detached and round with only a very 
small percentage undergoing morphological changes and attachment (Fig. 15).  
Despite morphological similarities between CD137 treated monocytes and 
classical mDCs, it is difficult to conclude that CD137 induces monocytes to 
differentiate to mDCs. DCs are a heterogeneous population of cells and there 
is no single surface marker that can unequivocally identify DCs (Shortman 
and Liu, 2002). Identification relies on the ability of cells to express or up-
regulate surface molecules that are involved in its maturation and the ability 
of DCs to activate T cells. Hence, in order to further characterize CD137 
treated monocytes, surface marker expression that is characteristic of DC 













Figure 15. CD137 treated monocytes undergo morphological changes. 
Monocytes were cultured under Fc or CD137-Fc treatment for 8 days. 
Additionally, monocytes were cultured in the presence of 80 ng/ml GM-CSF 
and 100 ng/ml IL-4 for 8 days to generate classical imDCs. Maturation of 
imDCs was induced by addition of 1 µg/ml LPS and 50 ng/ml IFN- during 
the last 18 h of culture (mDC). Photographs were taken on day 8 at a 
magnification of 630 X. Scale bar: 20 µm.  
 
 
One of the most characteristic features of DC maturation would be the up-
regulation of co-stimulatory molecule expression, CD80 and CD86 which are 
important in providing T cell co-stimulation for appropriate T cell priming. 
Indeed, both molecules were up-regulated upon CD137 treatment. Among 
CD137 treated monocytes that were further matured with LPS and IFN-, 
60% of cells were positive for CD80 expression with an MFI of 42 as 
compared to Fc treated cells of which only 48% of cells were positive with an 
MFI of 18. No difference in CD80 expression was observed in the absence of 
LPS and IFN-. CD86 expression on the other hand, was up-regulated upon 
CD137 treatment, even in the absence of further inflammatory stimuli (LPS + 




CD137 treated monocytes. In the presence of LPS and IFN-, no further 
increase in percentage of positive cells was observed but the MFI was 
increased from 108 to 202 which suggested greater expression of CD86 per 
cell. As expected, maturation of classical DCs with LPS and IFN-, up-
regulated expression of both CD80 and CD86. Expression of CD80 on DCs 
before and after maturation (74% and 93%, respectively) was higher than that 
of CD137 treated cells while expression of CD86 before maturation was only 
51%, which was lower than expression on CD137 treated cells. However, 
upon maturation expression was increased to 94% (Fig. 16).  
Apart from CD80 and CD86, CD83 is one of the best known maturation 
markers of human DCs (Zhou and Tedder, 1996; Lechmann et al, 2002). Fc 
treated monocytes show very little CD83 expression even in the presence of 
LPS and IFN- but CD137 treatment resulted in an up-regulation of CD83 to 
69% with an MFI of 46. Similar to CD86 expression, further inflammatory 
stimuli did not increase its expression. Classical DCs, before maturation 
showed a lower surface CD83 expression than CD137 treated monocytes but 
upon maturation, CD83 expression was increased to 92% of positive cells 
with an MFI of 107 (Fig. 16).  
Unexpectedly, expression of HLA-DR, a MHC II molecule, important in 
antigen presentation, was reduced in both CD137 treated monocytes and in 
classical DCs in the absence of further inflammatory stimuli. Addition of LPS 
and IFN- to both CD137 treated cells and classical DCs increased HLA-DR 
expression to levels comparable in Fc treatment. Despite these similarities 




Cell surface marker expression profile showed that classical DCs express DC-
SIGN and CD1a but CD137 treated monocytes did not (Fig. 16). DC-SIGN is 
a C-type lectin important in pathogen recognition by DCs (Geijtenbeek et al, 
2004) while CD1a mediates presentation of antigens to T cells and is a DC 
marker that is expressed early in development (Brigl and Brenner, 2004).  
The expression profile of CD137 treated monocytes which is similar to 
classical mDCs suggests that CD137L signalling induces monocytes to 
differentiate to mDCs. However, the absence of DC-SIGN and CD1a as well 
as the reduced HLA-DR expression, suggest that CD137 induces a different 
type of DC as compared to classical DCs generated in the presence of GM-
CSF and IL-4.  
Apart from their role in T cell activation, another important feature of DCs is 
their ability to migrate to lymph nodes after maturation where they can 
interact with T cells. This migration of DCs is regulated by the chemokine 
receptor CCR7. Indeed, CD137L signalling up-regulated CCR7 expression 
while CXCR4 expression was reduced. CCR7 expression was further up-
regulated in CD137 treatment in the presence of LPS and IFN-(Fig. 16).  
The surface expression profile of CD137 treated monocytes strongly 
suggested that CD137 can differentiate monocytes to DCs. However, to 
further confirm this, the ability of CD137 treated monocytes to induce T cell 




















































Figure 16. CD137 treated monocytes express markers typical of mDCs. 
Monocytes were cultured under Fc or CD137-Fc treatment. Additionally, 
monocytes were cultured in the presence of 80 ng/ml GM-CSF and 100 ng/ml 
IL-4 to generate imDCs. During the last 18 h of culture, 1 µg/ml LPS and 50 
ng/ml IFN- was added to each of the culture conditions. After 8 days of 
culture, cells were immunostained with the indicated surface markers and 
analysed by flow cytometry. Black and grey histograms represent isotype 
control and indicated surface markers, respectively. Numbers in histograms 








induce proliferation of T cells in an allogeneic MLR. CD137 treated 
monocytes enhanced proliferation of total T cells by 5 fold as compared to Fc 
treated monocytes (24835 ± 2768.9 and 4812.7 ± 1064.5 cpm, respectively) 
(Fig. 17A). Addition of LPS during the last 18 h of culture did not further 
increase the T cell stimulatory capacity of CD137 treated monocytes. This 
strongly implied that CD137 as a sole factor was able to differentiate 
monocytes to mDCs. CD137 treated monocytes were also more potent than 
classical DCs, generated by culturing monocytes in the presence of GM-CSF 
and IL-4 and matured by LPS, in their T cell stimulatory activity. Classical 
mDCs could only induce T cell proliferation to a cpm of 9282.7 ± 384.6 while 
cpm of T cells co-cultured with CD137 treated monocytes reached 24835 ± 
2768.9 (Fig. 17A). Previous studies have also shown that CD137 can be a 
maturation signal for classical DCs (Laderach et al, 2003; Lippert et al, 2008). 
Classical DCs matured with CD137-Fc were also more potent in inducing T 
cell proliferation than DCs matured with LPS but T cell proliferation was still 
lower than that of CD137 treated monocytes (Fig. 17A). These 3H-thymidine 
proliferation assays were further confirmed by CFSE based measurements of 
T cell proliferation. CFSE labelled T cells showed a decrease in MFI when 
co-cultured with CD137 treated monocytes as compared to Fc treated 
monocytes (861.6 and 1170.2, respectively). This decrease in MFI was 
accompanied by an increase in percentage of proliferating T cells upon co-
culture with CD137 treated monocytes. 51.9% of T cells were observed to be 
proliferating when co-cultured with CD137 treated monocytes as compared to 





The ability to induce total T cell proliferation is not restricted to DCs. 
Macrophages too are able to induce proliferation of memory T cells. 
However, naïve T cells are more resistant to activation and their proliferation 
can only be induced by DCs (Croft et al, 1994). A similar trend of T cell 
proliferation was observed when an MLR was performed with naïve 
CD45RA+ T cells. In fact, CD137 treated monocytes could increase naïve T 
cell proliferation by about 8 fold as compared to Fc treated cells (12256.7 ± 
1396.8 and 1480.7 ± 653.7, respectively). This fold increase observed in naïve 
T cells was greater than the fold increase observed with total T cells, even 
though, the absolute cpm count was lower in MLR with naïve T cells than that 
with total T cells. This lower absolute cpm count is not surprising as naïve T 
cells are more resistant to activation than total T cells (Fig. 17B). CFSE based 
T cell proliferation data further verified the 3H-thymidine assays. Stronger 
induction of naïve T cell proliferation upon co-culture with CD137 treated 
monocytes was also more evident in the CFSE assays. When co-cultured with 
CD137 treated monocytes, naïve T cells showed an MFI of 686 as compared 
to an MFI of 1053 in those co-cultured with Fc treated monocytes. The 
percentage of proliferating cells was also increased upon CD137 treatment as 
compared to Fc treatment (52.5% and 24.1%, respectively) (Fig. 17B).        
Similar to the trend with total T cells, addition of further inflammatory stimuli 
in the form of LPS and IFN- did not further increase the naïve T cell 
stimulatory activity of CD137 treated monocytes. These monocytes were also 
more potent than classical mDCs in inducing naïve T cell proliferation (Fig. 
17B). The ability for CD137 treated monocytes to induce proliferation of both 




to mDCs. Since these DCs were generated upon CD137L activation, they will 
henceforth be termed CD137L DCs.  
 
3.2.4 CD137L DCs and classical DCs are functionally different 
DCs are APCs that ensure development of appropriate adaptive immune 
responses. Control of T cell activation and polarization are usually dependent 
on cytokines produced by DCs. Hence the cytokine profile of CD137L DCs 
was analysed and compared to that of classical DCs.  
Cytokines that can influence T cell functions include IL-12, IL-23, IFN-, 
TGF- and IL-10. After 8 days of culture, IL-12 production could only be 
detected in supernatants of classical DCs which were matured with LPS and 
IFN-. CD137L DCs did not produce IL-12, even in the presence of LPS and 
IFN-. IL-23 production, however, was detected in supernatants of CD137L 
DCs only when LPS and IFN-was present. Similarly, IL-23 was detected in 
cultures of classical DCs only after maturation. Nevertheless, production of 
IL-23 by CD137L DCs was much more substantial than that by classical DCs 
(Fig. 18). IFN-was not detected in all culture conditions (data not shown). 
The cytokines, IL-12, IL-23 and IFN- are usually associated with a pro-
inflammatory state while IL-10 and TGF- are anti-inflammatory in nature. 
CD137L DCs produce low levels of IL-10 with or without LPS and IFN- 
treatment. Conversely, classical DCs increased IL-10 production upon 


















Figure 17. CD137 treated monocytes can induce T cell proliferation. 
Monocytes were cultured under Fc or CD137-Fc treatment. Classical imDCs 
were generated by culturing monocytes in the presence of 80 ng/ml GM-CSF 
and 100 ng/ml IL-4 for 8 days. During the last 18 h of culture, imDCs were 
matured with (A) 1 µg/ml LPS or (B) 1 µg/ml LPS and 50 ng/ml IFN- 
Classical imDCs were also matured in the presence of CD137-Fc or, as 
controls, Fc during the last 18 h of culture. On day 8, cells were harvested and 
co-cultured with allogeneic (A) total CD3+ T cells or (B) naïve CD45RA+, 
CD4+ T cells at a ratio of 1:10 (Monocytes:T cells). After 4 to 7 days, 
proliferation was quantified by (left panel) 3H-thymidine incorporation or 
(right panel) CFSE dilution. For 3H-thymidine incorporation means and 
standard deviations of triplicate measurements are depicted. Numbers in flow 
cytometry histograms represent percentage positive cells and MFI. *p<0.05; 




















































































production was also increased. However, its production was lower than that of 
DCs matured by LPS and IFN-(Fig. 18). Further, no TGF- was detectable 
under all culture conditions (data not shown). Absence of TGF-, inhibition of 
IL-10 and production of IL-23 suggest that CD137L DCs are pro-
inflammatory in nature.   
Similar to expression of maturation markers as described in section 3.2.3, 
differences were also observed in the cytokine profiles of CD137L DCs and 
classical DCs. This suggests that CD137L DCs and classical DCs can 
influence T cell polarization differently. Hence, these two DC types are not 
only phenotypically different but are most likely functionally different.  
 
3.3 Characterization of CD137L DC – T cell interactions 
The T cell stimulatory activity of CD137L DCs as described in section 3.2.3 is 
contradictory to the apoptosis inducing activity of CD137 treated monocytes 
as described in section 3.1.3. This section, therefore, hopes to reconcile these 
differences and to further examine T cell activation and polarization induced 
by CD137L DCs.     
 
3.3.1 CD137L DC-T cell interactions are biphasic in nature 
In the course of characterizing CD137 treated monocytes, two contrasting 
activities of CD137L signalling were observed. Short term treatment of 
























Figure 18. CD137L DCs produce inflammatory cytokines. Monocytes 
were cultured under Fc or CD137-Fc treatment. Additionally, monocytes were 
cultured in the presence of 80 ng/ml GM-CSF and 100 ng/ml IL-4 for 8 days 
to generate classical imDCs. During the last 18 h of culture, 1 µg/ml LPS and 
50 ng/ml IFN- were added to Fc and CD137-Fc treated cells and classical 
imDCs. Further, classical imDCs were matured in the presence of CD137-Fc 
during the last 18 h of culture. As controls, classical imDCs were cultured in 
the presence of Fc. On day 8, supernatants were harvested and concentrations 
of IL-23, IL-12p70 and IL-10 were determined by ELISA. Depicted are 
means ± standard deviations of triplicate measurements. n.d: non-detectable. 
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treatment, induced monocyte to differentiate to DCs which promoted T cell 
proliferation. These contradictory activities of CD137 seemed to be time 
dependent. A possible explanation for this observation would be that the 
effects of CD137 are temporally separated. Indeed, T cell apoptotic and 
stimulatory activities of CD137 treated monocytes were separated in time.      
When T cells and monocytes at a ratio of 5:1, were co-cultured right from the 
beginning (day 0), overnight CD137 treatment resulted in the expected 
increase in T cell apoptosis of 45.5% as compared to only 28.2% of apoptotic 
cells under Fc treatment. However, if monocytes were first cultured for only 1 
day in the presence of CD137 and T cells were added after monocyte pre-
treatment, no increase in the percentage of apoptotic cells was observed after 
overnight co-culture. The same trend was observed if monocytes were pre-
treated for 2 or 4 days before addition of T cells (Fig. 19A).  
The loss of T cell apoptosis inducing capabilities of CD137 treated monocytes 
was followed by their ability to induce proliferation of allogeneic T cells. 
Monocytes that were activated by CD137 for only 1 or 2 days failed to 
increase T cell proliferation. However, after 4 days of CD137 treatment, the 
ability of CD137 treated monocytes to induce T cell proliferation was 
increased by 2 fold as compared to untreated (PBS) or Fc treated monocytes 
(Fig. 19B). Hence, activities of CD137 treated monocytes can be divided into 
two phases: (1) only monocytes that were freshly activated by CD137 can 
induce T cell apoptosis and (2) prolonged CD137 treatment induces 
monocytes to differentiate to DCs (CD137L DCs) which are stimulatory to T 
cells. Following this, T cells that have been co-cultured with CD137L DCs are 
















































Figure 19. CD137L DC–T cell interaction occurs in two phases. (A) 
Monocytes were cultured under no treatment (PBS), Fc or CD137-Fc 
treatment. T cells, activated by 0.5 ng/ml of OKT3, were added to the 
monocyte cultures at a ratio of 5:1 (T cells: Monocytes). T cells were added at 
the beginning of the experiment (day 0) or 1, 2 or 4 days after monocyte had 
been cultured under the various treatments. After overnight co-culture, 
apoptosis was determined by Annexin V / 7AAD staining. Numbers in 
histogram represent percentage of cells in each quadrant. (B) Monocytes were 
cultured under no treatment (PBS), Fc or CD137-Fc treatment for 1, 2 or 4 
days. At each of these timepoints, monocytes were harvested and co-cultured 
with allogeneic T cells at a ratio of 1:10 (Monocyte: T cells). T cell 
proliferation was determined by 3H-thymidine incorporation 3 days after co-
culture. Depicted are percentages of proliferation as compared to proliferation 


























3.3.2 CD137L DCs promote a pro-inflammatory T cell phenotype 
DCs can determine the outcome of an immune response by inducing T cell 
activation and polarization. Hence, it would be of interest to determine how 
CD137L DCs influence T cell functions. The CD137L DC cytokine profile as 
described in section 3.2.4, suggested that these DCs are more likely to induce 
a pro-inflammatory rather than a regulatory or tolerogenic T cell phenotype. 
Indeed in T cells that were co-cultured with CD137L DCs, no expansion of 
natural Tregs, as characterized by CD4, CD25 and FOXP3 expression, was 
detected. In T cells that were co-cultured with Fc treated monocytes 44.5% of 
CD4+CD25+ cells were expressing FOXP3, the Treg specific transcription 
factor. In the presence of CD137L DCs, the expression of FOXP3 was  
reduced to only 6.5%. Further treatment of CD137L DCs with LPS did not 
further reduce the percentage of FOXP3 expressing cells. As expected, T cells 
co-cultured with classical imDCs showed high expression of FOXP3 of 
48.9%. This high percentage of FOXP3+ cells was reduced to 27.1% when T 
cells were instead cultured with classical DCs matured by addition of LPS. 
Nevertheless, the percentage of Tregs was still higher in cultures with 
classical mDCs than in those with CD137L DCs (Fig. 20).  
Apart from the natural Tregs, another subset of Tregs develop in the presence 
of TGF- and IL-10 and in turn produce the very same cytokines that induce 
its polarization i.e. TGF- and IL-10, to mediate their suppressive effects. 
These are designated Th3 and Tr1 cells, respectively (Jonuleit and Schmitt, 
2003). In addition to the absence of natural Tregs, it is highly unlikely that 




could be detected in MLR containing CD137L DCs. TGF- was also not 
detected in all culture conditions (data not shown). However, IL-10, another 
immunosuppressive cytokine, was detectable in supernatants of MLR 
cultures. IL-10 levels were increased from 128.8 ± 13.4 pg/ml in MLR 
cultures that contained Fc treated monocytes to 661.2 ± 164.5 pg/ml in 
supernatants of T cell co-cultured with CD137L DCs. Since CD137L DCs by 
itself produce low IL-10, the increased amounts of IL-10 in the MLR 
suggested that it was the T cell population that was producing IL-10. Addition 
of LPS and IFN- to CD137L DCs decreased production of IL-10 in the MLR 
as compared to those cultures which contained CD137L DCs. However, IL-10 
levels in MLR containing LPS and IFN- stimulated CD137L DCs were still 
significantly greater than that of its control i.e. MLR cultures that contained 
Fc treated monocytes stimulated with LPS and IFN- (Fig. 21A). This 
increase in IL-10 levels is unlikely to signify induction of T cell tolerance 
since development of Tr1 cells requires IL-10 and CD137L DCs showed low 
IL-10 production. Rather, increased IL-10 production might be a counter 
response to the highly pro-inflammatory environment that CD137L DCs 
induce. MLR cultures containing classical DCs whether mature or immature 
produced high levels of IL-10 (521.1 ± 12.0 and 487.2 ± 4.1 pg/ml, 
respectively), that were comparable to that of MLR cultures containing 
CD137L DCs. Highest IL-10 production was observed in co-cultures of T 
cells with classical DCs matured with CD137-Fc (Fig. 21A). Unlike CD137L 
DCs, where IL-10 production was most likely from T cells, it is uncertain if 







Figure 20. CD137L DCs reduce proportion of CD4+CD25+FOXP3+ cells. 
Monocytes were cultured under Fc, CD137-Fc or GM-CSF and IL-4 (DC) 
treatment for 8 days. Additionally, 1 µg/ml LPS was added for the last 18 h of 
culture. These monocytes were harvested and cultured with allogeneic T cells 
at a ratio of 1:10. After 5 days of co-culture, T cells were harvested, 
immunostained for CD4, CD25 and FOXP3 and analysed by flow cytometry. 
Histograms show expression of FOXP3 after gating in the CD4+CD25+ 
population. Numbers in histogram indicate percentage of positive cells and 










since cultures that only contained classical DCs already showed high IL-10 
production (Fig. 18). 
The inability of CD137L DCs to induce Tregs suggested that these DCs 
induce a pro-inflammatory T cell phenotype. Inflammatory T cells can be 
further divided into 3 subsets, Th1, Th2 and Th17, distinguishable by the 
cytokines that each subset produces. Th1 cells are usually characterized by the 
production of IFN-, Th2 cells by IL-4, IL-13 or IL-5 and Th17 cells by the 
production of IL-17 (Kadowaki, 2007; Kurts, 2008). Hence, the production of 
IFN-, IL-4, IL-13 and IL-17 was analysed.  
Interestingly, MLRs that contained CD137L DCs induced production of IFN-
, IL-13 and IL-17 which suggested activation of all three inflammatory Th 
cell subsets. Production of IL-17 was increased 10 fold in MLR that contained 
CD137L DCs as compared to MLR that contained Fc treated monocytes 
(3235.4 ± 186.0 and 359.1 ± 10.5 pg/ml, respectively). Addition of LPS and 
IFN- to CD137L DCs did not further increase IL-17 production in the MLR 
culture. Comparable levels of IL-17 produced by T cells in response to 
CD137L DCs in the absence and presence of LPS and IFN- is surprising as 
CD137L DC cultures did not produce the Th17 inducing cytokine, IL-23. IL-
23 was detectable only when CD137L DCs were treated with LPS and IFN-
Fig. 18). However, IL-23 neutralization studies suggested that CD137L 
DCs are indeed producing IL-23 but at levels that are probably too low to be 
detected by ELISA. In the neutralization assay addition of anti-IL-23 
antibodies to MLR containing CD137L DCs resulted in a decrease in IL-17 




added. Increasing the concentration of anti-IL23 antibodies from 1 µg/ml to 5 
µg/ml further decreased IL-17 production and suggested that IL-17 production 
induced by CD137L DCs was dependent on IL-23 (Fig. 22). Maturation of 
classical DCs with CD137-Fc also resulted in increased production of IL-17. 
In fact, IL-17 production was highest in MLR that contained classical DCs 
matured by CD137-Fc at a concentration of 5625.2 ± 13.6 pg/ml. In contrast, 
classical DCs matured with LPS and IFN- showed low IL-17 production 
(Fig. 21A). This data, therefore, suggested that CD137L DCs can induce 
activation of Th17 cells.  
Apart from IL-17 production, IFN- production was also increased to a high 
concentration of 5575.7 ± 20.8 pg/ml in MLR cultures that contained CD137L 
DCs while IFN- production by T cells co-cultured with Fc treated monocytes 
was almost non-detectable. Stimulation of CD137L DCs by LPS and IFN- 
did not further increase IFN- production by T cells. As expected, T cells co-
cultured with classical imDCs produced minimal IFN-. However, upon 
maturation by LPS and IFN- or CD137-Fc these DCs were able to induce T 
cells to produce high amounts of IFN- (7297.5 ± 155.5 and 5166.5 ± 620.4 
pg/ml, respectively) (Fig. 21A). The ability of CD137L DCs to induce IFN- 
production by T cells was further confirmed by an intracellular cytokine 
staining assay. T cells co-cultured with CD137L DCs indeed had a higher 
percentage of IFN-+ cells than T cells co-cultured with Fc treated monocytes 
(21.5% and 3.3%, respectively). This assay further showed that both CD4+ 
and CD8+ T cells produced IFN- upon co-culture with CD137L DCs but 




Intracellular cytokine staining also verified that classical mDCs could induce 
T cells to produce IFN- but the increase in percentage of IFN-+ cells was 
minimal compared to that induced by CD137L DCs (Fig. 21B). The increase 
in IFN- levels, detectable by ELISA and intracellular cytokine staining, in T 
cells co-cultured with CD137L DCs suggested that CD137L signalling 
induces or enhances Th1 responses. 
Unlike IFN- production where its levels were increased in the presence of 
mDCs, IL-4 levels remained undetectable in all culture conditions (data not 
shown). However, IL-13, another Th2 cytokine was detectable. IL-13 levels 
were low in supernatants of MLR that contained control monocytes. However, 
in the presence of CD137L DCs, IL-13 levels were significantly increased to a 
concentration of 1610.1 ± 42.0 pg/ml. T cells produced an even greater 
amount of IL-13 when cultured with CD137L DCs which were further 
activated by LPS and IFN- (2266.5 ± 35.7 pg/ml). Culture of T cells with 
classical mDCs, matured in the presence of LPS and IFN- or CD137-Fc, also 
increased IL-13 production. However, IL-13 levels were much lower than 
MLR cultures that contained CD137L DCs (Fig. 21A).   
Production of IL-17, IFN- and IL-13 suggested that CD137L DCs can induce 
activation of Th1, Th2 and Th17 cells in a total T cell population. This data 
together with the absence of Tregs indicate that T cells cultured with CD137L 
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Figure 21. CD137L DCs induce a pro-inflammatory T cell cytokine 
profile. Monocytes were cultured under Fc, CD137-Fc or GM-CSF and IL-4 
(DC) treatment for 8 days. Additionally, 1 µg/ml LPS or 1 µg/ml LPS and 50 
ng/ml IFN- were added for the last 18 h of culture. Classical DCs were also 
matured in the presence of Fc or CD137-Fc for the last 18 h of culture. 
Monocytes were then harvested and cultured with allogeneic T cells at a ratio 
of 1:10. (A) After 5 days of co-culture, supernatants were collected and levels 
of IL-10, IL-17, IFN- and IL-13 were determined by ELISA. Depicted are 
means ± standard deviations of triplicate measurements. *p<0.05; **p<0.01 
using a two-tailed unpaired Student’s t-test. (B) T cells were harvested, 
immunostained for CD4 and IFN- and analysed by flow cytometry. Numbers 





















Figure 22. CD137L DCs produce IL-23. Monocytes were cultured under Fc 
or CD137-Fc treatment for 8 days. After which, monocytes were harvested 
and cultured with allogeneic T cells at a ratio of 1:10. During the co-culture, 
anti-IL-23 antibodies at a concentration of 1 µg/ml or 5 µg/ml were added. As 
controls, no antibody or isotype control was added. After 5 days of co-culture, 
supernatants were harvested and levels of IL-17 were determined by ELISA. 


























3.3.3 CD137L DC induce production of IFN- and IL-13 but not IL-17 in 
naïve T cells 
Analysing the cytokine profile of CD137L DC treated T cells have suggested 
that these T cells are pro-inflammatory in nature. However, it does not show 
the type of T cell polarization that CD137L DCs support. Analysis of the 
naïve T cell cytokine profile may help to determine the induced T cell 
polarization. The cytokine profile of naïve T cells co-cultured with CD137L 
DC show similarities and differences to that of similarly treated total T cells. 
Unlike the total T cell population which produced high levels of IL-17 upon 
interaction with CD137L DCs (Fig. 21A), naïve T cells did not produce IL-17. 
IL-17 was not detectable in all culture conditions (data not shown). This 
suggested that CD137L DCs and classical DCs, whether matured with LPS 
and IFN- or CD137-Fc, do not induce Th17 polarization. However, in terms  
of IL-13 and IFN- production, cytokine profile of both total and naïve T cells 
were similar.  
Both CD137L DCs and classical mDCs showed significantly higher 
production of IFN-  and IL-13 in their MLR as compared to their respective 
controls i.e. MLR containing Fc treated monocytes and classical imDCs (Fig. 
23A). Levels of both cytokines were also comparable between the two T cell 
populations. In MLRs containing classical mDCs, IFN- levels were much 
higher than that of IL-13 (7455.7 ± 66.1 and 443.9 ± 14.1 pg/ml, 
respectively). This might suggest that classical DCs matured with LPS and 
IFN- promote Th1 T cell polarization. With CD137L DCs, it is difficult to 




levels were high in MLR that contained CD137L DCs (4554.3 ± 169.4 and 
3006.3 ± 83.7 pg/ml, respectively) (Fig. 23A). Analysis of Th1 and Th2 
specific transcription factors, T-bet and GATA-3, respectively, in T cells co-
cultured with CD137L DCs also failed to establish T cell polarization. Both 
transcription factors were equally up-regulated in T cells co-cultured with 
CD137L DCs (Fig. 23B). Nevertheless, the naïve T cell cytokine profile 
confirmed earlier observations that CD137L DCs induce T cells which are 
pro-inflammatory in nature and further showed that CD137L DCs do not 
support Th17 polarization.           
 
3.3.4 CD137L DCs increase the killing activity of CD8 T cells.  
CD137L DCs have been shown to induce activation of Th1 cells and increase 
IFN- production in CD8 T cells as described in section 3.3.2. This might 
indicate the ability of CD137L DCs to increase the cytolytic potential of CD8 
T cells. Cytolytic T cells mediate killing of target cells by two major 
pathways; granule dependent and independent pathways. The granule 
dependent pathway is mediated by the release of cytolytic proteins from lytic 
granules that are pre-formed in CD8 T cells (Trapani and Smyth, 2002). Two 
of the most well characterised cytolytic proteins include perforin and 
granzyme. 
Perforin expression in T cells that were cultured with various pre-treated 
monocytes was analysed. Perforin expression was observed in 50.6% of CD8+ 
T cells co-cultured with CD137L DCs as compared to 33.5% of CD8+ T cells 





































































































Figure 23. CD137L DCs induce Th1 and Th2 polarization. Monocytes 
were cultured under Fc, CD137-Fc or GM-CSF and IL-4 (DC) treatment for 8 
days. Additionally, 1 µg/ml LPS and 50 ng/ml IFN- were added for the last 
18 h of culture. Classical DCs were also matured in the presence of Fc or 
CD137-Fc for the last 18 h of culture. Monocytes were then harvested and 
cultured with allogeneic naïve CD45RA+, CD4+ T cells at a ratio of 1:10. (A) 
After 5 days of co-culture, supernatants were collected and levels of IFN- 
and IL-13 were determined by ELISA. Depicted are means ± standard 
deviations of triplicate measurements. **p<0.01 using a two-tailed unpaired 
Student’s t-test. (B) T cells were harvested, immunostained for CD3 and  
GATA-3 or T-bet and analysed by flow cytometry. Numbers in histograms 











increase the ability of CD137L DCs to induce perforin expression. Classical 
imDCs induced perforin expression comparable to that of Fc treated 
monocytes. Classical DCs matured with CD137-Fc failed to increase perforin 
expression in CD8+ T cells but maturation with LPS and IFN- increased the 
percentage of CD8+ T cells producing perforin to 43.1% (Fig. 24). 
Nevertheless, T cells which were cultured with CD137L DCs showed the 
highest expression of intracellular perforin, suggesting that CD137L DCs 
might be more potent than classical DCs in inducing cytolytic activities in T 
cells.  
Increased perforin expression in CD8 T cells may suggest an increased 
cytolytic potential but a more definitive test of the cytolytic activity would be 
to measure the killing capacity of CD8 T cells on target cells. In this killing 
assay, it was confirmed that increased perforin expression induced by 
CD137L DCs was accompanied by an increased ability of CD137L DC 
treated T cells to kill target cells (Fig. 25). Similar to the perforin expression 
profile, T cells co-cultured with CD137L DCs could initiate the highest 
percentage of apoptosis in K562 target cells (44.8%) while T cells co-cultured 
with Fc treated monocytes only induced apoptosis in 17.9% of target cells. 
Treatment of CD137L DCs with LPS and IFN- did not further increase their 
ability to induce killing activity of CD8 T cells. The killing activity of T cells 
co-cultured with classical imDCs, as measured by apoptosis of target cells, 
was comparable to that of T cells co-cultured with Fc treated monocytes. 
Maturation of classical DCs increased the killing capacity of T cells but the 
percentage of apoptotic cells was small compared to apoptosis induced by T 




Increasing the effector target cell ratio from 10:1 to 20:1 further increased the 
percentage of apoptotic cells in cultures containing CD137L DC treated T 
cells, indicating that apoptosis was induced by and was dependent on the 
presence of T cells (Fig. 25B).  
Ability of CD137L DC treated T cells to induce high apoptosis of K562 target 
cells indicated that CD137L DC can activate T cells with high killing 
potential. This study further showed that CD137L DCs are more potent than 
































Figure 24. CD137L DCs increase perforin expression in CD8+ T cells. 
Monocytes were cultured under Fc, CD137-Fc or GM-CSF and IL-4 (DC) 
treatment for 8 days. Additionally, 1 µg/ml LPS and 50 ng/ml IFN- were 
added for the last 18 h of culture. Classical DCs were also matured in the 
presence of Fc or CD137-Fc for the last 18 h of culture. Monocytes were then 
harvested and cultured with allogeneic T cells at a ratio of 1:10. After 5 days 
of co-culture, T cells were harvested, immunostained for CD8 and perforin 
and analysed by flow cytometry. Histograms indicate perforin expression in 
CD8+ cells. Numbers in histograms indicate percentages of positive cells and 






















Figure 25. CD137L DCs increase killing activity of CD8+ T cells. 
Monocytes were cultured under Fc, CD137-Fc or GM-CSF and IL-4 (DC) 
treatment for 8 days. Additionally, 1 µg/ml LPS and 50 ng/ml IFN- were 
added for the last 18 h of culture. Monocytes were then harvested and cultured 
with allogeneic CD8+ T cells at a ratio of 1:10. After 5 days of co-culture, T 
cells were harvested and co-cultured with CFSE labelled K562 target cells at 
effector to target cell ratios of 1:1, 10:1 and 20:1. After overnight co-culture, 
the percentage of apoptotic cells was determined by flow cytometry after 
Annexin V / 7AAD staining. (A) Flow cytometric histogram showing 
apoptosis of CFSE+ cells in cultures with effector to target cell ratio of 10:1. 
Numbers in histograms indicate percentages of cells in each quadrant. (B) 
Graphical representation of the percentage of apoptosis among CFSE+ cells at 






60 Fc CD137-Fc imDC mDC













This study highlights two contrasting activities of CD137L activated 
monocytes in affecting T cell proliferation and function. In characterizing the 
inhibitory effects of CD137 on PBMCs, T cells, both CD4+ and CD8+ T cells, 
were identified as the only cell type that underwent apoptosis in the presence 
of CD137. This CD137 induced T cell apoptosis was dependent on the 
presence of monocytes and required direct cell to cell contact. Expression of 
death inducing ligands and receptors, specifically the CD95 receptor and 
ligand pair and the TRAIL and death receptors, were up-regulated in T cells 
upon CD137 treatment and correlated with monocyte to T cell ratios. 
However, involvement of these death receptor and ligand systems in CD137 
induced, monocyte mediated T cell apoptosis could be excluded. Instead, 
increased ROS production in T cells was determined to be the initiator of 
CD137 induced, monocyte mediated T cell apoptosis.  
Further, evaluation of the effects of CD137L signalling showed that 
monocytes reduced typical macrophage activities such as phagocytosis, 
oxidative burst and CD14 expression. However, DC-like characteristics such 
as endocytosis and co-stimulatory molecule expression were up-regulated. 
Generation of DCs by CD137L activation was confirmed by the ability of 
CD137 treated monocytes to promote proliferation of both total and naïve T 
cells, and CD137 treated monocytes were therefore termed CD137L DCs. 
These CD137L DCs are phenotypically and functionally different from 
classical DCs matured in the presence of LPS or LPS and IFN-. CD137L 




show a greater T cell-stimulatory capacity than classical DCs. These CD137L 
DCs did not require further inflammatory stimuli for maturation as CD137 
treatment alone was sufficient to produce mDCs capable of activating naïve T 
cells. CD137L DCs, in turn, induce T cells that are pro-inflammatory in 
nature. CD137L DCs inhibit development of Tregs, but induce production of 
IFN-, IL-13 and IL-17. Further, T cells co-cultured with CD137L DCs show 
greater perforin production and killing of target cells than classical DCs. 
Hence, these DCs are more potent than classical DCs in inducing CD8 T cell 
killing activity.  
This T cell stimulatory activity of CD137L DCs was unexpected in light of 
the monocyte dependent T cell apoptotic activity of CD137. These two 
contrasting activities were attributed to the biphasic nature of CD137 treated 
monocytes. Exposure of T cells to monocytes freshly treated with CD137 
would mediate T cell apoptosis while its interaction with monocytes treated 
with CD137 for 8 days would promote T cell proliferation and activation. 
Hence, this study not only characterizes the T cell inhibitory activities of 
CD137L signalling, it also highlights the two phases of activation that CD137 
treated monocytes display and further shows the ability of CD137L activation 
to induce monocyte to DC differentiation. The following chapter discusses the 
significance of this biphasic property of CD137 treated monocytes and the 













Expression and function of the TNFR family member, CD137, is well 
documented in T cells. CD137 activation on T cells has been shown to 
preferentially promote proliferation, survival and increased activity of CD8 T 
cells as compared to CD4 T cells (Pollok et al, 1993; Alderson et al, 1993; 
Hurtado et al, 1994). Unlike these extensive studies on CD137, the effects of 
CD137L activation in T cells have been less well understood. Studies on the 
effects of CD137L stimulation in anti-CD3 stimulated PBMCs have implied 
that CD137L activation may be inhibitory to T cells (Schwarz et al, 1996; 
Michel et al, 1999). Unfortunately, these studies did not explicitly show 
induction of T cell apoptosis and failed to determine mechanism by which 
CD137L activation induces its inhibitory effects. This project shows, for the 
first time, that CD137 treatment specifically promotes apoptosis in T cells, 
with monocytes playing an important role in mediating these inhibitory 
effects. Further analysis of CD137L stimulation in monocytes reveals not only 
its inhibitory role in T cells but also the ability of CD137 treated monocytes to 
enhance pro-inflammatory T cell activities. This chapter therefore, discusses 
the mechanism by which CD137 mediates T cell apoptosis, the biphasic 
nature of CD137 treated monocytes, with regards to T cell inhibition and 
activation, and the consequence of such activities. The role of CD137 in 
mediating monocyte to DC differentiation will also be discussed and the 
possible use of CD137 in immunotherapy will be evaluated. Lastly, possible 







4.1 CD137L activated monocytes and their inhibitory activities on T cells 
The first section of this chapter discusses the inhibitory effects of CD137L 
activation in PBMCs, with particular emphasis on the T cell apoptotic 
activities of CD137L activated monocytes. The possible mechanism by which 
T cell apoptosis is induced and the physiological significance of such an 
activity is addressed. 
 
4.1.1 CD137 induces global inhibition of proliferation but selectively 
mediates T cell apoptosis 
Earlier studies by Schwarz et al have shown that culturing of anti-CD3 
stimulated PBMCs on CD137 expressing CHO cells can suppress 
proliferation and promote apoptosis of PBMCs (Schwarz et al, 1996).  Since 
CD137 induced inhibition of proliferation and induction of apoptosis occurred 
in the presence of anti-CD3 stimulation, the authors assumed that CD137 
negatively regulates T cell proliferation and survival within the PBMC 
population. However, neither inhibition of proliferation nor induction of 
apoptosis was clearly shown to be induced in the CD3+ subset within the 
PBMC population which consisted of monocytes, B cells, T cells and NK 
cells. 
Consistent with the findings of Schwarz et al, it was shown that immobilized 
CD137 protein could inhibit proliferation of anti-CD3 stimulated PBMCs 
(Schwarz et al, 1996). In addition, results from the present study show that 




proliferation of monocytes, B cells and NK cells. However, inhibition of 
proliferation was most prominent in the CD3+ population that represented the 
T cells. This decrease in the number of dividing cells could be a result of 
decreased cell viability upon CD137 treatment. Analysis of cell death in anti-
CD3 stimulated PBMCs showed that indeed CD137 treatment promoted cell 
death by apoptosis. The ability of CD137 treatment to promote apoptosis was 
confirmed by the increased percentage of Annexin V+ cells. Since Annexin V 
specifically binds to phosphatidylserine, increased Annexin V staining upon 
CD137 treatment suggest an increased externalization of phosphatidylserine, a 
hallmark of apoptosis.  
Unlike general inhibition of proliferation in the different PBMC subsets, 
apoptosis was induced specifically in the T cell population. Hence, it seems 
that CD137L signalling controls proliferation and apoptosis independently, at 
least in the monocyte, B cell and NK cell populations. The decrease in 
proliferation of both the monocyte and B cell populations is contradictory to 
earlier reports which showed that CD137L activation induced proliferation of 
monocytes and pre-activated B cells (Langstein et al, 1999; Pauly et al, 2002).  
These differences in observations may be attributed to the state of activation 
of these cells. In the study by Langstein et al, proliferation of monocytes 
correlated positively with the time monocytes were treated with CD137 and 
greatest proliferation was seen from day 7 to day 10 after CD137L 
stimulation. In the present study however, PBMC cultures were treated with 
CD137 for only 3 days before proliferation of the different subsets was 
determined. In B cells too, proliferation was only observed in pre-activated B 




al, 2002). Further, previous studies utilised pure monocyte or B cell 
populations while in the present study, a PBMC population consisting of 
monocyte, T cells, B cells and NK cells was used. Hematopoietic cells are 
known to be dynamic and interactions between the different subsets may 
influence the outcome of CD137L signalling in the monocyte and B cell 
populations.  
Nevertheless, the ability of CD137 treatment to decrease cell proliferation 
without affecting cell viability of the monocyte, B cell and NK cell 
populations, at least early upon CD137 treatment, may be an indication of 
activation and differentiation of these cells in response to CD137 stimulation. 
At least within the monocyte and B cell populations, several studies have 
shown that CD137L stimulation delivers an activating signal resulting in 
production of pro-inflammatory cytokines and immunoglobulin synthesis, 
respectively (Langstein and Schwarz, 1999; Langstein et al, 2000; Pauly et al, 
2002; Laderach et al, 2003).  
Studies on CD137L signalling in the NK cell population have been negligible, 
and the present study represents the first account of inhibition of NK cell 
proliferation upon CD137 treatment. In NK cells too, the pattern of 
proliferation and survival upon CD137 treatment is similar to that of 
monocytes and B cells and may be a consequence of NK cell activation. This 
hypothesis is further supported by the observed decrease in the percentage of 
total CD56+ cells after CD137 treatment (Fig. 4B). NK cells can be divided 
into the CD56bright CD16- and the CD56dim CD16+ subsets and the ontogeny of 
these cells are poorly understood (Cooper et al, 2001; Farag and Caliguiri, 




can differentiate into CD56dim cells both in vitro and in vivo, suggesting that 
the CD56dim NK cells are more mature and activated than the CD56bright cells 
(Chan et al, 2007). Hence, down-regulation of CD56 upon CD137 treatment 
may represent NK cell maturation and activation. However, greater analyses 
on the effects of CD137L stimulation on NK cell activity need to be done to 
confirm such a notion. All in all, the pattern of proliferation and apoptosis of 
the different PBMC subsets suggest that CD137L activation is possibly 
stimulatory to monocytes, B cells and NK cells but inhibitory only to T cells. 
 
4.1.2 CD137 induced T cell apoptosis requires monocyte help 
In contrast to the effects of CD137 treatment on monocytes, B cells and NK 
cells, T cells were the only cell type to undergo apoptosis within the PBMC 
population. The inhibition of proliferation and survival clearly showed that 
CD137 treatment is inhibitory to T cells. Since T cells are known to express 
CD137L after activation (Zhou et al, 1995), induction of T cell apoptosis after 
CD137 treatment could be a consequence of direct cross-linking of CD137L 
expressed on the anti-CD3 stimulated T cells by immobilized CD137 protein.  
In order to determine if inhibitory effects of CD137 treatment was due to 
interaction between CD137 and its ligand on T cells, a pure T cell population 
was isolated from PBMCs, activated with anti-CD3 antibodies to induce 
CD137L expression and cultured in the presence of CD137. Comparing the 
percentage of apoptotic cells in PBMC and pure T cell cultures after CD137 
treatment suggested that other cell types within the PBMC population were 




apoptotic cells in the pure T cell cultures upon CD137 treatment was only 
slightly higher than that of control cultures. In contrast, the percentage of 
apoptotic cells was increased 2 fold in PBMC cultures upon CD137 treatment 
(Fig. 5A). Among all the subsets of the PBMC population, monocytes 
represent the most probable cell type to influence T cell survival and function. 
Many studies have shown that monocytes upon stimulation can influence T 
cell polarization and activation and even induce T cell apoptosis (Wu et al, 
1996; Oyaizu et al, 1997; Wesch et al, 1998; Verreck et al, 2004; Anderson et 
al, 2002; Noel et al, 2004).  
It is not surprising then that the present study shows that CD137 mediated T 
cell apoptosis is dependent on the presence of monocytes as T cell apoptosis 
correlated positively with monocyte numbers in the CD137 treated cultures. 
CD137 mediated, monocyte dependent T cell apoptosis bears close 
resemblance to MDCD. MDCD has characteristically been described in 
mediating T cell apoptosis when co-cultured with mitogen activated 
monocytes. Several studies have used monocytes activated with various 
mitogens including PMA and phytohaemagglutinin (PHA) (Wu et al, 1996; 
Wesch et al, 1998). In these studies, similar to the present study, T cell 
apoptosis was dependent on the number of monocytes in the culture, induction 
of cell death required direct cell to cell contact between monocytes and T cells 
and soluble factors alone were insufficient in inducing T cell apoptosis. So 
far, these studies have been performed in the presence of experimental 
mitogens and the physiological stimulus of MDCD remains uncertain.  
Some studies have implicated certain viruses, including hepatitis C virus 




facilitate disease progression. In the HCV model, MDCD is proposed to limit 
immune responses to the viruses and therefore prevent viral clearance while in 
HIV infection, MDCD seems to mediate apoptosis of uninfected bystander T 
cells but not HIV infected T cells (Herbein et al, 1998; Nakamoto et al, 2001). 
From these studies, MDCD seems to be a general term used to describe T cell 
apoptosis induced by activated monocytes. Since expression of CD137 on 
most cell types is activation dependent, CD137 could be one of the 
physiological initiators of MDCD.  
 
4.1.3 CD137 mediates T cell apoptosis independently of the extrinsic 
pathway of apoptosis 
The ability of the CD137 receptor / ligand system to induce apoptosis is not 
unique within the TNF and TNFR superfamily. The CD95 receptor / ligand 
and the death receptor / TRAIL systems are some of the best characterized 
death inducing proteins and constitute part of the extrinsic pathway of 
apoptosis (Fulda and Debatin, 2006). However, unlike the other proteins 
within the TNF and TNFR superfamily, death is induced by the CD137 
receptor / ligand pair upon reverse signalling. In the CD95 receptor / ligand 
and death receptor / TRAIL systems, apoptosis is typically initiated in the 
receptor bearing cells. Further, unlike other death inducing proteins within the 
TNF and TNFR superfamily, the cytoplasmic domain of CD137L lacks the 
death domain required for the assembly of the death inducing signalling 
complex (DISC) required to initiate apoptosis (Kischkel et al, 1995; Sprick et 




inducing proteins to mediate its T cell apoptotic effects. Consequently, the 
requirement for monocytes in mediating CD137 induced T cell apoptosis is 
not surprising.   
The necessity for cell to cell contact between monocytes and T cells in 
mediating CD137 induced apoptosis suggests that cell surface molecules are 
involved in mediating T cell death upon CD137L signalling. Of course, the 
most obvious candidate in this case would be CD95. The role of CD95 in 
mediating apoptosis in the immune system has been relatively well 
documented. This molecule has been implicated in mediating T cell apoptosis 
during negative selection in the thymus and during AICD (Walczak and 
Krammer, 2000). Michel et al has shown that CD137 can induce the 
expression of CD95 on T cells. The present study further show that CD137 
can induce expression of CD95L in T cells and that this expression correlated 
positively with monocyte numbers. However, consistent with a study by 
Michel et al, neutralizing anti-CD95 antibodies failed to rescue CD137 
mediated T cell apoptosis. In MDCD too, conflicting data exists for the 
involvement of CD95. Several reports have associated CD95 with MDCD. In 
these studies, neutralizing CD95 antibodies and soluble CD95-Fc fusion 
protein could inhibit T cell apoptosis induced by monocytes (Wu et al, 1996; 
Oyaizu et al, 1997). However, other studies show T cell inhibition to be 
independent of CD95 (Wesch et al, 1998; Munn et al, 1999). These 
differences in the mechanism by which MDCD occurs may be a result of the 
different mitogens used to activate the monocytes, and not surprisingly come 




highlights the diversity of MDCD and, as discussed in section 4.1.2, further 
suggests that MDCD is not mediated by one mechanism only.  
Apart from excluding the role of CD95 in CD137 induced T cell apoptosis, 
the present study further shows that apoptosis is mediated independently of 
the death receptors / TRAIL system. Similar to CD95, apoptosis induced by 
TRAIL has an important part to play in exerting immunosuppressive and 
immunoregulatory functions important for T cell homeostasis (Falschlehner et 
al, 2009). In the present study, it was shown that expression of TRAIL, DR4 
and DR5 were induced in T cells but not monocytes upon CD137 treatment 
and expression of these surface proteins correlated positively with monocyte 
numbers. However, similar to the CD95 death receptor pathway, involvement 
of TRAIL in CD137 induced T cell apoptosis can be excluded since 
neutralizing anti-TRAIL antibodies failed to prevent T cell apoptosis.     
The present study therefore excludes the role of the extrinsic pathway of 
apoptosis in mediating CD137 induced T cell apoptosis. The significance of 
up-regulation of these death inducing proteins upon CD137 treatment is 
unclear. However, it could represent a natural response of T cells to 
activation. Early up-regulation of these death inducing proteins may be a 
mechanism to allow for quick down-regulation of immune responses during 







4.1.4 ROS in T cells is important in mediating CD137 induced MDCD 
With the exclusion of CD95 and TRAIL in mediating CD137 induced 
MDCD, T cell apoptosis upon CD137 treatment is most probably mediated 
through the intrinsic pathway. The intrinsic pathway of apoptosis typically 
involves mitochondrial depolarisation and cytochrome c release which 
eventually leads to activation of the caspase cascade leading to apoptosis 
(Zamzami and Kroemer, 2001). Studies in the lab have shown that indeed 
CD137 treatment resulted in a loss of mitochondrial membrane potential 
leading to mitochondrial membrane permeabilization and consequent release 
of cytochrome c (personal communication, Nurulhuda M.), suggesting that 
CD137 induces T cell apoptosis via the intrinsic pathway. 
The intrinsic pathway of apoptosis is characteristically induced in response to 
intracellular stress such as hypoxia, growth factor deprivation, defective cell 
cycle or DNA damage (Green and Kroemer, 2004; Kim et al, 2006). Elevated 
ROS levels within a cell can also lead to generalized oxidative damage to 
mitochondrial components and induce apoptosis. Shortly after activation, T 
cells have been reported to produce ROS, probably due to increased activity 
of the mitochondrial transport chain, leading to increased production of 
superoxide. This production of ROS can regulate activation-induced T cell 
apoptosis and have been suggested to play a role in peripheral T cell deletion 
(Hildeman et al, 1999; Hildeman et al, 2003).  
In MDCD too, Wesch et al have shown that catalase can block T cell 
apoptosis by mitogen activated monocytes. Indeed, CD137 induced MDCD 




could completely rescue T cells from CD137 induced MDCD. Further work in 
the lab also showed that scavenging of superoxide and inhibition of NOX, an 
NADPH oxidase that reduces oxygen to superoxide, can also completely 
rescue CD137 induced T cell apoptosis. On the whole, interaction between 
CD137 treated monocytes and T cells seem to increase ROS production in T 
cells through the activity of NOX, leading to induction of apoptosis. Since 
direct cell to cell contact between monocytes and T cells is required for 
CD137 induced T cell apoptosis and soluble factors alone are insufficient to 
mediate T cell apoptosis, interaction between CD137 treated monocytes and T 
cells most probably occur through a surface protein. Unfortunately, the 
surface molecule involved in this interaction, which leads to elevated ROS 




Figure 26. Involvement of ROS in CD137 induced T cell death. Schematic 
representation of ROS involvement in CD137 induced T cell apoptosis. The 
identity of the grey receptor / ligand pair that mediates superoxide production 
in T cells remains unknown. NOX: NADPH oxidase; O2- : superoxide; SOD: 





4.1.5 Physiological significance of CD137 induced MDCD  
Apoptosis is a tightly regulated process and in T cells, apoptosis has generally 
been associated with (1) maintenance of central and peripheral tolerance, (2) 
maintenance of T cell homeostasis and (3) removal of activated T cells 
especially during the resolution phase of an infection. This may help to 
prevent the development of autoimmune diseases and inflammation that can 
be detrimental to the host (Brenner et al, 2008). Since in the present study, T 
cell apoptosis is observed in anti-CD3 stimulated cells, the possibility of 
CD137 induced MDCD in maintaining central T cell tolerance can be 
overlooked. It is also unlikely that CD137 induced MDCD is involved in the 
resolution of an infection.  
Two concepts of T cell apoptosis have been described to be involved in the 
shutting down of an immune response; AICD and activated T cell autonomous 
death (ACAD). AICD describes apoptosis induced in T cells upon 
restimulation of the TCR and can be mediated by both intrinsic and extrinsic 
pathways of cell death (Krammer, 2000; Green et al, 2003). ACAD, however, 
does not require TCR restimulation, depends on the intrinsic cell death 
pathway and contributes to down-regulation of T cell numbers during the 
resolution phase (Hildeman et al, 2002). Both AICD and ACAD have been 
suggested to work together to bring about down-regulation of immune 
responses. Hence, a feature of both activated T cell death pathways require 
that the immune response and consequently, activation of T cells, have taken 
place for some time. In such a case, T cells would have become overly 
activated or T cell survival signals would be lacking, resulting in AICD and 




occurs within 24 h of CD137 treatment and during suboptimal T cell 
activation. This suggests that CD137 induced T cell apoptosis is unlikely to 
mediate T cell death at the end of an immune response.  
Moreover, in CD137 induced MDCD, T cell apoptosis was induced only 
when T cells were co-cultured with monocytes from the beginning of CD137 
treatment. When monocytes were first treated with CD137 prior to T cell co-
culture, no T cell apoptosis was observed. Instead, T cell proliferation was 
induced when T cells were co-cultured with monocytes that had been treated 
with CD137 for at least 4 days (Fig. 19). This observation further disputes the 
role of CD137 induced MDCD in mediating resolution of an infection. Rather, 
the pattern of CD137 induced MDCD bears close resemblance to infection 
induced T cell attrition.  
In a number of viral infections including infections by measles virus, 
influenza virus and LCMV, severe lymphopenia develops in humans 
(Nabeshima et al, 2002; Schneider-Schaulies and Schneider-Schaulies, 2009). 
In mice, severe lymphopenia after LCMV infection is accompanied by the 
expansion of LCMV specific T cells and B cells, 2 to 4 days postinfection 
(Peacock et al, 2003; Bahl et al, 2006). A similar phenomenon was also 
observed when an immunostimulant that mimics viral infections was 
administered to mice (Bahl et al, 2010). However, conflicting data exists on 
whether T cell attrition early in a viral infection is restricted to bystander T 
cells or to memory antigen specific T cells (McNally et al, 2001; Jiang et al, 
2003; Bahl et al, 2010). Nevertheless, these studies show that T cell attrition 
which occurred during the first 24 h of infection is accompanied by expansion 




once antigen-specific T cells receive survival and growth signals, probably 
from activated APCs. This pattern of T cell death and subsequent T cell 
proliferation is similar to that of CD137 treated PBMC or T cell – monocyte 
co-cultures whereby T cell apoptosis occurs during the first 24 h, after which, 
upon sufficient activation of monocytes by CD137, T cell proliferation is 
induced 4 days post CD137 treatment.    
Logically, this early virus induced T cell attrition suggests that early depletion 
of T cells can be disadvantageous to the development of an immune response 
in the host. However, the converse is observed. It has been demonstrated that 
initial lymphopenia can lead to enhanced immune responses by creating space 
in the lymphoid organs for development and expansion of antigen specific T 
cells (Peacock et al, 2003). Further, Bahl et al have shown, through computer 
modelling, that early T cell attrition can function to deplete low-affinity cross-
reactive T cells that can skew an immune response. This allows for 
development of a more diverse and higher affinity T cell response towards the 
immunodominant epitopes of the pathogen (Bahl et al, 2006).  
Studies in the lab show that CD137 expression is indeed up-regulated upon 
influenza virus infection (personal communication, Jiang D.). Hence, virus 
induced CD137 can mediate early T cell attrition in the form of MDCD and 
subsequently allow for the development of a more robust immune response. 
Further, CD137 not only induces T cell apoptosis early, prolonged treatment 
of monocytes with CD137 can also mediate T cell proliferation, polarization 
and activation (discussed in the later sections of this chapter). Therefore, 
CD137L signalling, as a whole, is geared towards the development of a pro-




mediating the effects of CD137 induced MDCD, the following sections 
discusses the role of CD137 in monocyte differentiation and the consequent 
effects of interaction between prolonged CD137 treated monocytes and T 
cells.  
 
4.2 CD137L activation induces monocyte differentiation that is 
stimulatory to T cells 
The following section of this chapter characterizes the effects of CD137L 
signalling on monocyte differentiation. The consequent interaction between 
CD137L DCs and T cells is also discussed and the potential of developing 
CD137L DCs as a DC based vaccine is addressed.  
 
 4.2.1 CD137L signalling inhibits monocyte to macrophage differentiation 
Studies on the effects of CD137L signalling in monocytes have shown that 
CD137L activation results in the production of pro-inflammatory cytokines, 
inhibition of anti-inflammatory cytokines and adherence of monocytes which 
is accompanied by morphological changes (Langstein and Schwarz, 1999; 
Langstein et al, 1999; Sollner et al, 2007). All these changes can be attributed 
to the activating effects of CD137L stimulation on monocytes. So far, in vitro 
and in vivo evidences suggest a role of CD137 in monocyte recruitment and 
extravasation, possibly at sites of inflammation (Drenkard et al, 2007; Quek et 
al, 2010). However, no further studies have been done to look at how CD137 




The present study represents the first in-depth characterization of the effects 
of CD137L activation in monocytes. 
The present study showed that CD137L expression can be detected on resting 
monocytes and treatment of monocytes with immobilized CD137-Fc or 
agonistic anti-CD137L antibodies induced production of the pro-inflammatory 
cytokine, IL-8. Hence, consistent with other reports, this suggests that 
monocytes express CD137L constitutively and that stimulation of CD137L on 
monocytes is activating. Physiologically, circulating monocytes can migrate 
into tissues and further differentiate to macrophages and dendritic cells, 
depending on the micro-environmental signals. This allows for maintenance 
of tissue homeostasis and control and resolution of an infection. Studies by 
Jiang et al suggested that CD137 can function as a differentiation factor for 
monocytic cells. Both in human and murine hematopoietic progenitor cells, 
CD137 could induce proliferation and differentiation to the myeloid lineage, 
specifically to macrophages but not to DCs (Jiang et al, 2008(a); Jiang et al, 
2008(b)). As such it is probable that CD137 can also promote differentiation 
of peripheral monocytes to macrophages.  
Macrophages are APCs that mature continuously from circulating monocytes 
and utilise innate immune mechanisms to counter pathogenic invasions. As 
one of the first cells to respond to an infection, macrophages are involved in 
ingesting pathogens by the process of phagocytosis to clear an infection. Upon 
phagocytosis macrophages can activate the production of various ROS 
through the process of oxidative burst to kill ingested pathogens. Phagocytosis 
also serves to allow for processing of antigens from ingested pathogens and 




both phagocytosis and oxidative burst represent key macrophage functions 
that are important in clearance of an infection. Analysis of both phagocytosis 
and oxidative burst capacity of CD137 treated monocytes can confirm if 
indeed, similar to CD137 treated hematopoietic cells, CD137 can induce 
monocytes to differentiate to macrophages.  
Surprisingly, treatment of monocytes with CD137 inhibited both macrophage 
functions i.e. phagocytosis and oxidative burst. Inhibition of these 
macrophage functions occurred as early as 1 day after CD137 treatment. This 
may suggest that CD137 treatment, though activating, may render the 
monocytes non-functional. However, comparison of the phagocytic ability of 
CD137 treated monocytes to that of classical macrophages and DCs suggests 
otherwise. After seven days of culture, the phagocytic profile of CD137 
treated monocytes is comparable to that of classical DCs while classical 
macrophages show a high phagocytic capacity. This indicates that CD137 
treated monocytes are indeed functional but instead of promoting macrophage 
differentiation, CD137 supports DC differentiation. If that is the case, then the 
decrease in the oxidative burst capacity of CD137 treated monocytes is not 
surprising since unlike macrophages, the primary function of DCs is not to 
kill ingested pathogens but to uptake and present antigens. 
The CD14 expression and endocytic activity of CD137 treated monocytes 
further suggest that CD137 inhibits macrophage differentiation while 
promoting DC differentiation. CD14 is a monocyte and macrophage marker 
and its down-regulation suggests that CD137 does indeed induce monocyte 
differentiation but its differentiation to macrophages is inhibited. Further, as 




present antigens. Hence, DCs, in the immature state, should characteristically 
possess high endocytic capacity. Unlike inhibition of phagocytosis and 
oxidative bursts capacity, CD137 treated monocytes show an increased 
endocytic activity as early as 1 day after CD137 treatment, with highest 
endocytosis observed, seven days after CD137 treatment. The high endocytic 
capacity of CD137 treated monocytes argues against the generation of non-
functional macrophages. Rather, similarities in the functional profile of 
CD137 treated monocytes to that of classical DCs suggest that CD137 
promotes monocyte to DC differentiation.    
This inhibition of macrophage differentiation and induction of DC 
differentiation in monocytes by CD137 is in sharp contrast to the effects of 
CD137L signalling on the differentiation of hematopoietic cells whereby 
differentiation to macrophages is instead supported. Differences in CD137 
induced differentiation in these two cell populations could be attributed to the 
different maturation states of the cells. Circulating peripheral monocytes are 
of course more differentiated than hematopoietic progenitor cells and have 
been exposed to endogenous myeloid growth factors during the course of their 
development and as such, the CD137L signal is sufficient to induce DC 
differentiation. Since hematopoietic progenitor cells are less mature and more 
plastic, it is possible that they require other growth factors, in addition to 







4.2.2 CD137 promote monocyte to differentiate to inflammatory DCs  
Classical DCs and CD137 treated monocytes show similar functional profiles, 
in terms of phagocytosis and endocytic potential which suggested that CD137 
treatment induces monocyte to DC differentiation. However, such functional 
profiling is insufficient to claim that CD137L signalling indeed promotes 
monocyte to DC differentiation. So far, others have reported that CD137 can 
induce maturation of imDCs but none have shown a DC differentiation 
potential of CD137 (Kim et al, 2002; Laderach et al, 2003; Lippert et al, 
2008).  
Similar to published studies, the present study showed that CD137 treatment 
promoted monocyte adherence and morphological changes (Sollner et al, 
2007). In this study, monocytes were cultured under CD137 treatment for as 
long as eight days and the viability of CD137 treated monocytes were 
maintained throughout the long culture period. Many morphological 
similarities were observed between CD137 treated monocytes and classical 
DCs that have been matured by the addition of LPS and IFN-. This 
morphological similarity represents the first evidence that perhaps CD137 not 
only induces monocyte to DC differentiation but that it also participates in 
inducing the maturation of CD137L DCs. This is not surprising in light of 
evidences which have shown that CD137 can be used as a maturation factor 
for classical DCs. Even so, greater analyses of typical DC characteristics are 
important in characterizing CD137 as a DC differentiation factor.   
Even though DCs are a heterogeneous population of cells, their identification 




stimulatory molecules and most importantly on their ability to induce T cell 
proliferation. Indeed, the present study showed that CD137 treated monocytes 
show an up-regulation of the DC maturation marker, CD83, and the co-
stimulatory molecules, CD80 and CD86. Further, CCR7, the chemokine 
receptor up-regulated upon DC maturation and involved in DC migration 
from the periphery to the lymph nodes (Forster et al, 1999; Gunn, 2003; 
Randolph et al, 2005), is also up-regulated upon CD137 treatment. This 
migration of DCs to the lymph node is important for the interaction between 
DCs and T cells and hence is crucial for the development of an adaptive 
immune response. However, reduced MHC class II expression and the 
absence of CD1a and DC-SIGN make the claim that CD137L signalling 
induces monocyte to DC differentiation questionable. Nevertheless, CD137 
treated monocytes were able to induce proliferation of total T cells and most 
importantly, naïve T cells. The ability of CD137 treated monocytes to induce 
proliferation of naïve T cells undoubtedly indicates the DC differentiation 
potential of CD137.  
Of interest is that these CD137L DCs could promote up-regulation of CD83, 
CCR7 and co-stimulatory molecules and induce T cell proliferation in the 
absence of further pro-inflammatory stimuli, suggesting that CD137L DCs are 
already mature, and this sets CD137 apart from other DC differentiation 
factors. In vitro DC generation classically involves a two-step process. The 
first involves the differentiation of monocytes to imDCs and is followed by 
DC maturation in the presence of pro-inflammatory stimuli (Banchereau and 
Steinman, 1998; Tuyaerts et al, 2007). Morphological changes induced by 




induce naïve T cell proliferation, show that CD137 as a single factor alone is 
sufficient to induce differentiation and maturation of DCs. Therefore, the 
induction of CD137L signalling represents the simplest protocol to generate 
mDCs.    
Even so, addition of the pro-inflammatory stimuli, LPS and IFN-, to CD137L 
DCs did induce greater expression of CD80, CD86, MHC class II and CCR7 
on CD137L DCs and was necessary for IL-23 production. However, this did 
not translate to a greater potential in inducing both total and naïve T cell 
proliferation. T cell proliferative capacity of CD137L DCs in the presence or 
absence of further pro-inflammatory stimulus was comparable to each other.      
This ability of CD137 in inducing mDCs without the addition of further pro-
inflammatory factors may be attributed to the production of pro-inflammatory 
cytokines such as IL-6, IL-8 and especially TNF, which is known for its 
maturation stimulating activity, upon CD137L stimulation. Several studies 
have shown that indeed CD137L activation in monocytes promotes the 
production of IL-6, IL-8 and TNF (Langstein et al, 1998; Langstein et al, 
2000; Sollner et al, 2007). Further, Lippert et al have shown that maturation 
of classical DCs by CD137 was blocked in the presence of neutralizing anti-
TNF antibodies. As such it would not be too far-fetched to assume that pro-
inflammatory cytokines produced in response to CD137L stimulation are 
responsible in inducing maturation of CD137L DCs. 
Surface marker expression profiling suggests an immunogenic potential of 
CD137L DCs. However, it is the cytokine profile of DCs that indicates their 




Tolerogenic DCs have been defined to be immature, maturation resistant or 
are alternatively activated and characteristically produce high amounts of IL-
10 and are impaired in their ability to produce IL-12 (Li et al, 2005; Morelli 
and Thomson, 2007). Since CD137L DCs induce low IL-10 production and 
do not produce TGF-, it is highly unlikely that CD137L DCs are tolerogenic 
in nature. Production of IL-23 by CD137L DCs, though only in the presence 
of LPS and IFN-, further disputes the possibility that CD137L DCs are 
tolerogenic. Rather, CD137L DCs are more likely to be pro-inflammatory in 
nature. Of course, effector functions of CD137L DCs would best be 
characterised in terms of their T cell activation capacities and this will be 
discussed in the sections below.  
 
4.2.3 CD137L DCs are phenotypically and functionally different from 
classical DCs 
Since CD137 induces monocyte to DC differentiation, CD137L DCs were 
compared to classical DCs, generated by stimulating monocytes with GM-
CSF and IL-4. This represents the most common method of generating large 
amounts of DCs from peripheral blood monocytes (Tuyaerts et al, 2007). 
However, whether DCs differentiate physiologically in response to GM-CSF 
and IL-4 is unknown. At least in the case of CD137, its expression is induced 
during immune responses and expression is strictly activation dependent. 
Therefore, CD137 might have a role to play in the development of 




Initial comparison of the phagocytic activity, endocytic capacity and 
morphological changes of CD137L DCs and classical DCs, show that both 
types of DCs are highly similar. However, upon phenotypic characterization 
and greater functional analysis, differences in both DC types are observed. Of 
course one of the most obvious differences is that CD137L DCs do not require 
further pro-inflammatory stimuli for maturation while classical DCs require 
addition of LPS and IFN- to induce their maturation. CD137L DCs and 
classical DCs also differ in their surface marker expression, cytokine 
production and T cell stimulatory capacity. Phenotypically, classical DCs 
express high levels of CD1a and DC-SIGN while no expression of these 
molecules was observed on CD137L DCs. Different subtypes of DCs are 
known to exist both in man and mice. In the lymphoid tissues of mice, five 
different DC subtypes have been identified, based on the expression of CD11b 
and CD205 while in the spleen three different subtypes are consistently 
observed, namely CD4-CD8+, CD4+CD8- and CD4-CD8- (Vremec et al, 2000; 
Shortman and Liu, 2002). In the skin too, Langerhans cells are typically found 
in the epidermal layer while dermal DCs can be classified according to the 
expression of CD103 and CD11b (Ginhoux et al, 2009). Unfortunately, in 
man, characterization of the different DC subtypes is limited and human blood 
DCs have been described to be heterogeneous in the expression of a range of 
markers (Shortman and Liu, 2002). To date, it is unclear if these different 
subtypes develop from separate lineages or represent different activation 
states of a single lineage. Hence, differences in surface marker expression of 




subtypes of DCs expressing different surface markers that have been 
characterised. 
More important than analysing surface marker expression, is to classify DCs 
according to their effector functions and their T cell stimulatory activities. 
Based on allogeneic MLR, CD137L DCs have a greater T cell proliferative 
potential than classical DCs, both in induction of total and naïve T cell 
proliferation. The T cell proliferative potential of CD137L DCs was also 
greater than that of CD137 matured classical DCs. The potency of CD137L 
DCs in inducing T cell proliferation, despite the lower MHC class II 
expression levels as compared to classical DCs, may be attributed to the 
reduced IL-10 production by CD137L DCs. While classical DCs produce high 
levels of IL-10 upon maturation, CD137L DCs produce low levels of IL-10 
even in the presence of LPS and IFN-. Effector functions of DCs are dictated 
by the cytokines they produce and this is influenced by the pro-inflammatory 
signals that DCs receive. Therefore, it is possible that the choice of a different 
maturation signal that inhibits IL-10 production of classical DCs may have 
comparable potency in inducing T cell proliferation as CD137L DCs. 
Nevertheless, in the present study, IL-10 production was induced upon 
maturation of classical DCs with both CD137 and LPS and IFN-. This might 
likely reflect a tendency of GM-CSF and IL-4 differentiated DCs to produce 
IL-10 and hence, induce less potent T cell proliferative effects than CD137L 
DCs. 
IL-10 is an immunosuppressive cytokine and as mentioned in section 4.2.2, 




inhibits IL-10 production. Though classical DCs produce large amounts of IL-
10, they are also unlikely to promote development of tolerogenic DCs as high 
IL-12 production is induced upon its maturation. Therefore, both CD137L 
DCs and classical DCs would most likely be stimulatory towards T cell 
activation. However, both these DC types may influence T cell development 
and activation differently due to differences in induction of IL-12 and IL-23 
production. Therefore, CD137L DCs and classical DCs are not only 
phenotypically different but are also functionally different.  
 
4.2.4 CD137L DCs promote inflammatory T cells with a high killing 
activity 
Cytokine profiles of CD137L DCs and classical DCs which show high 
production of IL-23 and IL-12, respectively, suggest that each of these DC 
populations promote different T cell activation profiles and indeed, such is the 
case. Differences were observed in production of IL-17, IL-13 and IL-10. 
However, IFN- production was comparable among total T cells stimulated 
with CD137L DCs and those stimulated with classical mDCs. Even so, when 
IFN- production was analysed intracellularly, the pattern of IFN- production 
induced by the two DC populations was distinct. While classical mDCs 
induce IFN- equally in both CD4+ and CD8+ T cells, CD137L DCs induce 
greater IFN- production in CD8+ T cells than in CD4+ T cells. This might 
imply differences in CD8 T cell activation capacities of CD137L DCs and 




The present study show that CD137L DCs support activation of all 
inflammatory Th cell subsets as production of IFN-, IL-13, and IL-17, 
indicative of Th1, Th2 and Th17 activation, respectively, could be detected in 
T cell cultures treated with CD137L DCs. Even classical DCs matured with 
CD137 could induce production of all three cytokines in T cells. This 
distinguishes CD137L DCs or DCs matured with CD137 from classical mDCs 
which only show high production of IFN-This high production of IFN- by 
T cells treated with classical mDCs is not surprising considering the high 
amounts of IL-12 that classical mDCs produce. However, production of IFN- 
and IL-17 by T cells cultured with CD137L DCs is unexpected.  It has been 
well documented that IL-12 and IL-23 are required for polarization of T cells 
towards Th1 and Th17, respectively. Since IL-12 production could not be 
detected in CD137L DC cultures and IL-23 was detectable only in CD137L 
DC cultures that were treated with LPS and IFN-, production of IFN- and 
IL-17 by T cells treated with CD137L DCs and without LPS and IFN- 
activation was surprising. 
Since Th17 polarization not only depends on IL-23 but also on IL-6 and TGF-
 (Aggarwal et al, 2003; Bettelli et al, 2006; Veldhoen et al, 2006), it is 
possible that these other cytokines mediate activation of Th17 cells by 
CD137L DCs. It has been well established that CD137L stimulation induces 
IL-6 production by monocytes (Langstein et al, 1998) and hence, IL-6 could 
be mediating Th17 activation by CD137L DCs. Alternatively, IL-23 is indeed 
produced by CD137L DCs but produced at levels too low for detection by 
ELISA. IL-23 neutralization studies seem to suggest so as the addition of anti-




production. The same might apply to the production of IL-12 by CD137L 
DCs. However, several studies have suggested that minimal IFN- production 
can be induced by an IL-12 independent pathway but IL-12 is an absolute 
requirement for optimal production of IFN- in T cells (Verhagen et al, 2000; 
Losana et al, 2002). Other studies indicate that IL-12 production by DCs 
requires two signals and depends on the presence of IFN- (Snijders et al, 
1998; Kitagawa et al, 2001) and therefore, it is possible that CD137L DCs 
initially induce minimal production of IFN- in T cells by an IL-12 
independent pathway. The IFN- that is produced in turn stimulates CD137L 
DCs to produce IL-12 that is important for the high production of IFN- that 
was observed in T cells co-cultured with CD137L DCs. 
Apart from high production of IFN-, IL-17 and IL-13, CD137L DCs also 
increased production of IL-10 by T cells. However, increased production of 
IL-10 is unlikely to signify development of Tregs, especially since CD137L 
DCs by themselves produce low levels of IL-10 which is a cytokine required 
for the development of Tr1 cells, a subset of Tregs. This is further supported 
by the observation that T cells stimulated by CD137L DCs lose expression of 
the Treg-specific transcription factor, FOXP3. Rather, increased IL-10 
production in T cells treated with CD137L DCs may be a consequence of the 
highly pro-inflammatory environment that CD137L DCs induce. Hence, IL-
10 as an immunosuppressive cytokine can help to down-regulate 
inflammation induced by CD137L DC treated T cells.  
To this point, induction of IFN-, IL-17 and IL-13 in total T cells suggest that 




does not imply that CD137L DCs can induce polarization of Th1, Th2 and 
Th17 cells. Indeed, such is the case as IL-17 was not detectable in naïve T 
cells treated with CD137L DCs. Only high production of IL-13 and IFN-was 
observed in these cultures. Together with the observed T-bet and GATA-3 
expression in these T cells, it indicates that CD137L DCs support both Th1 
and Th2 polarization.  
Cytokine profiling of T cells shows that CD137L DCs induce T cells that are 
pro-inflammatory in nature and these T cells support Th1 activities that are 
important for the activation of CD8 T cells. Further, CD137L DCs 
preferentially induced IFN- production in CD8 T cells. Perforin expression 
of CD137L DC treated T cells was the highest as compared to classical DCs 
matured with CD137 or LPS and IFN-. This is suggestive of the high killing 
potential of CD137L DC treated T cells and was confirmed by a killing assay. 
CD8 T cells co-cultured with CD137L DCs were the most efficient at killing 
the target cells, even more than classical mDCs. Hence, CD137L DCs not 
only induce pro-inflammatory T cells, they can also promote high killing 
activity of CD8 T cells. As such, there may be a potential for the use of 
CD137L DCs in human immunotherapy.  
 
4.2.5 The potential of using CD137L DCs as a tool in human 
immunotherapy 
The ability of DCs to activate and influence adaptive immune responses to a 
variety of diseases has for a while generated much interest in DC based 




proven to be successful when applied to the mice system (Ardavin et al, 
2004). Unfortunately, DC based vaccines have only showed minimal clinical 
responses. As such, much research has focused on determining factors that 
would increase the anti-tumour activities of DCs in humans. These include 
determining (1) cytokines that are involved in ex vivo generation of DCs, (2) 
maturation factors that are beneficial towards development of anti-tumour 
immune responses, (3) ideal antigens that should be loaded onto DCs and (4) 
effective routes of DC delivery to tumours (Tuyaerts et al, 2007; Ilett et al, 
2010). To date, studies are continually being done aiming to generate DCs 
with potent anti-tumour activities in the shortest possible time.  
Typically, DCs that are considered to have potential for use in human 
immunotherapy produce high levels of IL-12, IFN- and IL-6 while 
suppressing IL-10 production (Tuyaerts et al, 2007). With such a cytokine 
profile, it is hoped that these DCs would induce the development of an anti-
tumour Th1 immune response. The present study show that CD137 can induce 
monocytes to differentiate to DCs that suppress IL-10 production, induce T 
cell proliferation, promote high IFN- production by T cells, activate T cells 
to increase perforin expression and most importantly, generate T cells with 
high potential cytolytic and apoptotic capacities. Moreover, CD137L DCs are 
more potent than classical mDCs in their T cell stimulatory activity and in 
inducing killing activity of T cells. Hence, CD137 show potential in 
developing DCs that may be effective in tumour immunotherapy. Further, the 
present study shows that CD137 as a single factor is sufficient in inducing 
differentiation and maturation of DCs and therefore represents the simplest 




maturation factors for development of appropriate T cell responses. Hence, 
CD137L DCs show potential for use in DC based immunotherapy and further 
studies should focus on characterizing CD137L DCs in more detail, and 
ultimately on determining the efficacy of CD137L DCs in an in vivo setting. 
 
4.3 Conclusion 
It has been well established that CD137L signalling results in monocyte 
activation. However, these studies have been restricted to the characterization 
of monocyte activation in terms of morphological changes and cytokine 
production. Further, the time course of monocyte activation is generally 
limited to a short stimulation period by CD137-Fc. Only a study by Langstein 
et al showed the effects of prolonged culturing of monocytes on CD137. Even 
so, monocyte activation was only determined by the production of the pro-
inflammatory cytokine, IL-8, and the effects of CD137 on monocyte survival 
and proliferation were examined (Langstein et al, 2000). The present study 
represents the first analysis of the effects of CD137L activation on monocyte 
differentiation and their subsequent interactions with T cells.  
This discussion has highlighted two opposing effects of CD137 treated 
monocytes with regards to their interaction with T cells. Short activation of 
monocytes with CD137 is shown to induce T cell apoptosis. However, with 
prolonged CD137 treatment, monocytes differentiate to DCs that are capable 
of inducing T cell proliferation and stimulating inflammatory T cells that have 
a high killing activity. As discussed in section 4.1.5, this pattern of inducing 




resemblance to infection induced T cell attrition. Overall, such a pattern of T 
cell apoptosis and activation is expected to be beneficial during the course of 
an immune response. Since CD137 is expressed only in the event of an 
inflammation and its expression is strictly activation dependent, CD137 can 
most likely influence antigen specific T cell responses in two ways. Firstly, 
early interaction between CD137L activated monocytes and T cells would 
promote T cell apoptosis, thereby eliminating low-affinity cross-reactive T 
cells and generating space for amplification of pathogen specific T cells. 
Secondly, CD137L activated monocytes can participate in the development 
and expansion of pathogen specific T cells that help to effectively clear the 
infection. Therefore, physiologically, CD137L signalling is geared towards 
development of a pro-inflammatory immune response.  
Further, the present study shows that in an in vitro setting, CD137L DCs are 
more potent than classical DCs in stimulating T cell proliferation. CD137L 
DC treated T cells also show a greater killing activity than T cells activated by 
classical mDCs. Since CD137 can by itself induce differentiation and 
maturation of monocytes to DCs, it represents the easiest protocol for 
generation of mDCs. This reflects the potential of using CD137 in generating 
DCs that can be used for human immunotherapy. However, both the role of 
CD137 in infection induced T cell attrition and the potential for development 
of CD137L DCs as a tool in human immunotherapy need to be further 






4.4 Future work  
The present study has shown that interactions between CD137L stimulated 
monocytes and T cells occur in two phases. Firstly, short activation of 
CD137L on monocytes is inhibitory to T cells and secondly, prolonged 
CD137L activation differentiates monocytes to DCs that are stimulatory to T 
cells. Hence, future research on CD137L biology of monocytes should 
address these two opposing activities of CD137L activated monocytes. 
 As has been discussed in section 4.1.5, the pattern of CD137 induced 
monocyte dependent T cell apoptosis fits that of infection induced T cell 
attrition. Most of the published data on infection induced T cell attrition has 
been gained in murine models while the present study show effects of 
CD137L signalling in human monocytes. It would be important to establish if 
the same effects of CD137L signalling are operational in murine cells. This 
would allow for in vivo studies to be performed in murine models. CD137 and 
CD137L deficient mice would prove useful in these in vivo studies as it would 
allow for quantification of infection induced T cell attrition in wildtype and 
CD137 or CD137L deficient mice.  
Further, the present study shows that CD137L stimulation inhibits 
proliferation of NK cells while maintaining their viability. It has been 
suggested in section 4.1.1, that this might potentially signify an activation of 
NK cells. Since not much is known about effects of CD137L stimulation on 
NK cells, more research should be focused on determining NK cell activity 
after CD137 treatment. Since the cytolytic activity is the most important 




activation alters NK cells’ cytolytic activity. Alternatively, the effects of 
CD137 treatment on expression of NKG2D, one of the major triggering 
receptors on NK cells, can be determined. This might reflect the sensitivity of 
NK cells’ killing activity after CD137 treatment.  
Apart from the role of CD137 treated monocytes on T cell apoptosis, the 
present study also established the role of CD137 in generating CD137L DCs. 
These DCs have the potential for use in human immunotherapy. However, 
more work needs to be done to develop CD137L DCs as an attractive DC 
based vaccine. The present study shows that CD137L DC treated T cells have 
a high killing activity but stimulation of T cells was not antigen specific and 
depended on the allogenicity of the two cell populations. Hence, it would be 
of interest to determine if CD137L DCs have the same effect on the cytolytic 
activity of T cells in an antigen specific setting. Two antigen specific models 
can be established; an infectious disease model and a tumour model.  
Additionally, the potency of CD137L DCs should be compared to DCs that 
have been used in human immunotherapy. In the present study, maturation of 
classical DCs was induced by addition of LPS and IFN-a common method 
of inducing in vitro DC maturation. However, DCs used in immunotherapy 
cannot be matured by LPS since LPS can be toxic to the intended recipient. 
Most commonly used is a cocktail of pro-inflammatory factors which include 
IL-6, IL-1, TNF and PGE2. More recently, synthetic proteins such as 
Monophosphoryl Lipid A, oligodeoxynucleotides containing 
immunostimulatory motifs and Ribomunyl are used to induce maturation of 




CD137L DCs should be compared to classical DCs that are matured by these 
clinical grade maturation factors.  
Most importantly, it would be necessary to determine the efficacy of CD137L 
DCs in eradicating tumours in an in vivo setting. This data is crucial in 
developing CD137L DCs for use in human immunotherapy. However, several 
challenges need to be addressed. This includes the choice of an animal model, 
choice of tumour, loading of tumour antigens and route of delivery of 
CD137L DCs to the animal. It is hoped that future research can help to 
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APPENDIX 1 TISSUE CULTURE MEDIA 
A1.1 RPMI 1640  
 For a 1 L preparation,  
 RPMI powder (Sigma-Aldrich) 16.35 g 
 L-glutamine (200mM) (Gibco, Invitrogen) 10 ml 
 Sodium bicarbonate (Sigma-Aldrich) 2.0 g 
 MilliQ water Top up to 1L 
   
A1.2 R10  
 For a 1 L preparation,  
 RPMI-1640 medium 900 ml 
 FBS (Biowest) 100 ml 
   
A1.3 R10 + P/S  
 For a 1 L preparation,   
 R10  990 ml 
 Penicillin / Streptomycin (Gibco, Invitrogen) 10 ml 
   
A1.4 IMDM  
 IMDM powder (Sigma-Aldrich) 17.7 g 
 L-glutamine (200mM) 10 ml 
 Sodium bicarbonate 3.02 g 
 MilliQ water Top up to 1L 




A1.5 I10  
 IMDM medium 900 ml 
 FBS 100 ml 
 
The pH of all culture media was adjusted to 7.4. Medium was sterile filtered 


















APPENDIX 2 BUFFERS FOR ISOLATION OF PBMCS AND PBMC 
SUBSETS  
A2.1 PBS + 2mM EDTA  
 For a 1 L preparation,  
 10 X PBS (1st Base) 100 ml 
 EDTA (0.5M) (1st Base) 4 ml 
 MilliQ water Top up to 1L 
   
A2.2 RBC lysis buffer  
 For a 1 L preparation,  
 NH4Cl (Sigma-Aldrich) 8.29 g 
 NaHCO3 (Sigma-Aldrich) 0.84 g 
 EDTA (0.5M)  23 µl 
 MilliQ water Top up to 1L 
   
A2.3 MACS buffer  
 For a 1 L preparation,   
 10 X PBS  100 ml 
 EDTA (0.5M) 4 ml 
 0.5% BSA (Biowest) 5 g 
 
The pH of buffers was adjusted to 7.4. Buffers were sterile filtered through a 





APPENDIX 3 MISCELLANEOUS BUFFERS 
A3.1 Trypsin-EDTA  
 For a 50 ml preparation,  
 0.5% Trypsin-EDTA (Gibco, Invitrogen) 5 ml 
 10 X PBS 5 ml 
 MilliQ water Top up to 50 ml 
   
A3.2 10 mM EDTA in PBS  
 For a 50 ml preparation,  
 EDTA (0.5M) 1 ml 
 10 X  PBS 5 ml 
 MilliQ water Top up to 50 ml 
   
A3.3 FACS buffer  
 For a 1 L preparation,   
 FBS  5 ml 
 Sodium azide (Sigma-Aldrich) 0.2 g 
 10 X PBS 100 ml 
 MilliQ water Top up to 1L 
 
The pH of buffers was adjusted to 7.4. Trypsin-EDTA and 10 mM EDTA in 
PBS were sterile filtered through a 0.22µm filter membrane before use. 
 
